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Abstract 
Transcriptional silencing is a major cause for the inactivation of tumor suppressor genes, 
however, the underlying mechanisms are only poorly understood. The EPHB2 gene encodes 
a receptor tyrosine kinase that controls epithelial cell migration and allocation in intestinal 
crypts. Through its ability to restrict cell spreading, EPHB2 functions as a tumor suppressor 
in colorectal cancer whose expression is frequently lost as tumors progress to the carcinoma 
stage. Previously we reported that EPHB2 expression depends on a transcriptional enhancer 
whose activity is diminished in EPHB2 non-expressing cells. Here we investigated the 
mechanisms that lead to EPHB2 enhancer inactivation. We show that expression of EPHB2 
and SNAIL1 - an inducer of epithelial-mesenchymal transition (EMT) - is anti-correlated in 
colorectal cancer cell lines and tumors. In a cellular model of Snail1-induced EMT, we 
observe that features of active chromatin at the EPHB2 enhancer are diminished upon 
expression of murine Snail1. We identify the transcription factors FOXA1, MYB, CDX2 and 
TCF7L2 as EPHB2 enhancer factors and demonstrate that Snail1 indirectly inactivates the 
EPHB2 enhancer by downregulation of FOXA1 and MYB. In addition, Snail1 induces the 
expression of Lymphoid enhancer factor 1 (LEF1) which competitively displaces TCF7L2 
from the EPHB2 enhancer. In contrast to TCF7L2, however, LEF1 appears to repress the 
EPHB2 enhancer. Our findings underscore the importance of transcriptional enhancers for 
gene regulation under physiological and pathological conditions and show that SNAIL1 
employs a combinatorial mechanism to inactivate the EPHB2 enhancer based on activator 
deprivation and competitive displacement of transcription factors. 
 
Keywords 
Epithelial-mesenchymal transition, transcriptional enhancer, EPHB2, FOXA1, MYB, LEF1  
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Abbreviations: 
 
cDNA: complementary DNA 
ChIP: chromatin immunoprecipitation 
CRC: colorectal cancer 
DHS: DNase I hypersensitive sites 
Dox: doxycycline 
ECR: evolutionary conserved region 
EMSA: electrophoretic mobility shift assay 
EMT: epithelial-mesenchymal transition 
FAIRE: formaldehyde-assisted isolation of regulatory elements 
HA: hemagglutinin  
HUVEC: human umbilical vein endothelial cells  
LEF: lymphoid enhancer factor 
qPCR: quantitative PCR 
qRT-PCR: quantitative reverse transcriptase PCR 
RT-PCR: reverse transcriptase PCR 
SEM: standard error of the mean 
TCF: T-cell factor 
TUB: TUBULIN 
TSS: transcriptional start site 
WT: wild-type  
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1. Introduction 
 
Transcriptional enhancers are defined as cis-regulatory DNA elements that increase the 
activity of homologous and heterologous promoters independently of distance and orientation 
(reviewed in: [1]). Enhancer DNA contains clusters of transcription factor binding sites and 
provides a platform for the assembly of multi-component regulatory protein complexes that 
increase the activity of a linked promoter by various mechanisms, for example by eliciting 
chromatin structural changes, by recruitment of RNA polymerase II, or by direct promoter 
communication through the MEDIATOR complex [1]. Enhancers exist in different functional 
states that are distinguished by characteristic structural features. Inactive or latent enhancers 
resemble bulk chromatin whereas active enhancers are nucleosome-free or associated with 
specific histone variants and bound by transcriptional regulators. Nucleosomes flanking 
active enhancers show higher ratios of the H3K4me1/2 and H3K4me3 marks compared to 
promoter regions, and are enriched for the H3K27ac mark that is replaced by H3K27me3 at 
poised enhancers [1]. These distinguishing structural characteristics allow for enhancer 
functional states to be experimentally probed by DNase I hypersensitive site (DHS) mapping, 
formaldehyde-assisted isolation of regulatory elements (FAIRE) and chromatin 
immunoprecipitation (ChIP) using antibodies for transcription factors, histones, or histone 
modifying enzymes such as the acetyltransferases p300/CBP [1]. Transcriptional enhancers 
play key roles in the spatiotemporal control of gene expression during organismal 
development. Likewise, the importance of enhancers in disease states and their contribution 
to the activation of oncogenes and the silencing of tumor suppressors are increasingly 
recognized [1-5]. In this regard it is of considerable interest to understand how faulty 
activation or inactivation of transcriptional enhancers is brought about. 
 
 EMT denotes the occurrence of profound changes in the cellular phenotype that are 
observable under various physiological and pathological conditions [6, 7]. Cells undergoing 
EMT lose the apical-basal polarity as well as the cell-cell and cell-matrix adhesions 
characteristic of epithelial cells. Instead, they acquire a fibroblast-like morphology with front-
to-rear end polarity and gain increased motility and invasive capacities. These phenotypic 
changes are reflected by massive alterations in gene expression patterns [7]. In recent years, 
EMT has received significant attention in the area of cancer research. For instance, EMT 
was proposed to facilitate tumor cell invasion and dissemination, it was implicated in the 
acquisition of cancer stem cell properties, and it was shown to confer acquired resistance 
towards apoptosis, radiation and chemotherapy [6-11]. Pathological forms of EMT can be 
induced by a variety of tumor-cell intrinsic but also environmental signaling cascades all of 
which ultimately induce the expression of one or several members of the SNAIL, ZEB, and 
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TWIST families of DNA binding proteins [6, 7]. These EMT inducing transcription factors 
primarily act as transcriptional repressors but can also activate gene expression. Although 
numerous genes are known that are directly or indirectly regulated by EMT inducers, only 
very limited mechanistic information exists to explain how changes in gene expression are 
achieved during EMT. 
 
 The EPHB2 gene encodes a receptor tyrosine kinase that is expressed in the stem 
cell population located at the base of the crypts of Lieberkühn in the intestinal epithelium [12, 
13]. Under physiological conditions, EPHB2 receptor activity has substantial mitogenic 
effects and additionally controls cell migration and cell positioning along the crypt axis [12, 
14]. The ability of EPHB2 to restrict cellular movement is thought to underlie EPHB2 tumor 
suppressor function in CRC and the loss of EPHB2 expression seems to facilitate tumor cell 
invasion [15, 16]. 
 
 A known regulator of EPHB2 expression in the intestine is the Wnt/β-catenin pathway 
[12, 17]. Wnt/β-catenin signaling is of critical importance during development and adult 
homeostasis of the gastro-intestinal tract [18]. Aberrant Wnt/β-catenin pathway activity also 
plays a key role throughout all stages of colorectal tumorigenesis [19]. A central aspect of 
this pathway is the control of the transcriptional co-activator function of β-catenin. Upon 
pathway activation by ligand/receptor interactions or by mutation of certain pathway 
components, β-catenin enters the nucleus where it interacts with diverse transcription factors 
[18]. However, the lion’s share of Wnt/β-catenin transcriptional responses is mediated by 
complexes formed between β-catenin and members of the TCF/LEF family which in humans 
is comprised of LEF1, TCF7, TCF7L1 and TCF7L2 [20]. Although all TCF/LEF proteins share 
certain structural similarities including the β-catenin binding domain and the highly conserved 
HMG-box DNA binding domain, amino acid sequences outside these domains show 
considerable divergence [20]. As a result, significant functional differences among TCF/LEF 
proteins exist [21-24]. 
 
 As a Wnt/β-catenin target gene, EPHB2 shows a particular, biphasic temporal 
expression profile in the course of intestinal tumorigenesis. EPHB2 expression increases in 
the wake of Wnt/β-catenin pathway hyperactivation at the onset of colorectal tumorigenesis. 
However, initial upregulation of EPHB2 is frequently followed by secondary downregulation 
at the adenoma-carcinoma transition which is in agreement with the known role of EPHB2 as 
a tumor suppressor [15, 25-27]. How EPHB2 expression is silenced and becomes uncoupled 
from Wnt/β-catenin signaling is not completely understood. Several recent findings prompted 
us to explore a potential mechanistic link between EMT and enhancer inactivation. For 
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instance, in a model of SNAIL1-induced EMT, EPHB2 is subject to late stage 
downregulation, which argues that EPHB2 may be indirectly repressed by SNAIL1 [28]. 
Furthermore, in a previous study we identified a transcriptional enhancer within the EPHB2 
5’-flanking region [2]. This enhancer displays cell-type-specific activity and loss of enhancer 
function was observed in EPHB2 non-expressing CRC cells even in the presence of Wnt/β-
catenin pathway activating mutations. This suggested that EPHB2 enhancer inactivation 
contributes to EPHB2 secondary silencing. However, the underlying cause for EPHB2 
enhancer decommissioning and whether SNAIL1 contributes to this remained unknown. We 
now report that SNAIL1 downregulates the transcription factors MYB and FOXA1, which are 
required for EPHB2 enhancer function. Moreover, SNAIL1 induces expression of LEF1, 
which replaces TCF7L2 at the EPHB2 enhancer. This switch in occupancy by two 
functionally different Wnt/β-catenin effectors appears to abrogate Wnt responsiveness of 
EPHB2. Overall, our results provide insights into the molecular workings of EPHB2 enhancer 
inactivation during EMT. The observed complexity of this multi-faceted process offers new 
perspectives for the mechanistic understanding of enhancer decommissioning and might 
also be pertinent to other models. 
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2. Materials and methods 
 
2.1. Bioinformatic analyses of microarray gene expression data 
 
For comparative expression analyses of EPHB2 and SNAI1/LEF1 in the transcriptomes of 
human colorectal tumors and cell lines, the normalized microarray datasets GSE14333 (290 
colorectal tumor samples) and GSE59875 (155 CRC cell lines) were obtained from The 
Gene Expression Omnibus Website (http://www.ncbi.nlm.nih.gov/geo/). Absolute gene 
expression levels were obtained by averaging over multiple probesets for the same gene, 
and relative expression levels by standardizing each gene to have mean zero and standard 
deviation one over all samples. Samples were sorted according to highest difference in 
expression levels between EPHB2 and SNAI1/LEF1 and the relative expression values of 
EPHB2 and SNAI1/LEF1 are shown. The pairwise Pearson correlation coefficient between 8 
genes of interest was calculated from the same microarray datasets. Genes were clustered 
in the pairwise correlation matrix using single linkage with Euclidean distance as previously 
described [2]. To examine the association between the expression of EPHB2 and either an 
EMT gene set or the EPHB2 enhancer factor gene set, we calculated the mean of the 
absolute expression values for all components of each gene set. Subsequently, the pairwise 
linear correlation coefficients between the gene set expression value and the absolute 
expression value of EPHB2 for each tumor sample or CRC cell line was determined. 
 
 
2.2. Statistical analysis 
 
The mean of three independent biological replicates with the corresponding standard error of 
the mean (SEM) was taken in order to represent all quantitative data. In the case of 
quantitative PCR analyses and luciferase reporter assays, the numerical values for each 
biological replicate were determined by duplicate measurements (two technical replicates) of 
a given sample. For calculation of statistical significance an unpaired, two-tailed Student’s t-
test was used unless otherwise indicated. Numbers of asterisks represent statistically 
significant changes with the following P values: * P < 0.05, ** P < 0.01, *** P < 0.001. 
 
 
2.3. Identification of evolutionary conserved regions and sequence analyses  
 
Evolutionary conserved regions (ECRs) were identified using the ECR browser 
(http://ecrbrowser.dcode.org/) [29] which defines regions with at least 70% nucleotide 
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sequence identity over 100 bp as ECRs. Transcription factor binding sites were determined 
using MotifMap (http://motifmap.ics.uci.edu) and the JASPAR database 
(http://jaspar.binf.ku.dk) [30, 31]. DHS and chromosomal regions with high levels of the 
histone modifications H3K4me1 and H3K27ac in human umbilical vein endothelial cells 
(HUVEC) were obtained from the UCSC Genome Browser using the Human Feb. 2009 
(GRCh37/hg19) Assembly (http://genome.ucsc.edu/) [32]. 
 
 
2.4. Plasmid construction and cloning 
 
To generate luciferase reporter constructs covering portions of the human EPHB2 upstream 
region, DNA fragments were amplified by PCR from genomic DNA isolated from LS174T 
cells and blunt-end cloned into pZERO (Invitrogen/Life Technologies, Darmstadt, Germany). 
Restriction enzymes SacI and NheI were used to transfer the fragments into the 
pGL3promoter plasmid (Promega, Heidelberg, Germany) by standard cloning techniques. 
EPHB2 upstream fragments with nucleotide sequences corresponding to positions -8398/-
8330, -8350/-8272 and -8350/-8330 relative to the transcriptional start site were generated 
via annealing of equal amounts of complementary oligonucleotides in 1x NEB buffer 2 for 5 
min at 95°C followed by 60 min of slow cooling to room temperature. Sequences of the 
oligonucleotides used are listed in Table 1. Mutagenesis of transcription factor binding sites 
was performed according to the Stratagene QuikChange
TM
 site-directed mutagenesis 
protocol. Oligonucleotide primers used are listed in Table 1. Successful mutagenesis was 
verified by sequencing. The CDX2 coding region was amplified by PCR using pDONR223-
CDX2 as template (kindly provided by the BIOSS Toolbox, Freiburg, Germany) with the 
following primer pair: 5′-GGATCCGCATGTACGTGAGCTACCTCCTGGACAA-3′ and 5’-
TTCGAACTGGGTGACGGTGGGGTTTAGC-3′. The resulting PCR product was cut with 
BamHI and BstBI and ligated into a derivative of the pCS2+ plasmid [33] providing the coding 
region for a hemagglutinin (HA)-tag. The MYB coding region (containing an HA-tag) was 
released from pCI-neo-MYB (kindly provided by K.-H. Klempnauer, University of Münster, 
Germany) with XhoI and XbaI and ligated into pCS2+. Expression vectors for human 
TCF7L2-E and mouse Lef1 were previously described [34]. For the generation of stably 
transduced cell lines for Dox-inducible expression of Lef1-HA, the coding region for Lef1-HA 
was cloned into the pRetroX-tight-Pur vector (Clontech, Saint-Germain-en-Laye, France) by 
standard cloning techniques. For the generation of stably transduced cell lines for Dox-
inducible expression of SNAIL2-HA, the coding region for SNAIL2-HA was cut out from 
pCS2+SNAIL2-HA and cloned into the pRetroX-tight-Pur vector [28]. The stably transduced 
cell lines for Dox-inducible expression of ZEB1-HA were generated by releasing the coding 
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region of human ZEB1-HA with NotI and Bsp120I from the plasmid pTET Bsr HA-ZEB1-IRES 
berry [35] (kindly provided by T. Brummer, University of Freiburg, Germany) and cloning into 
the pRetroX-tight-Pur vector (Clontech, Saint-Germain-en-Laye, France). 
 
 
2.5. Cell culture 
 
The CRC cell lines LS174T (CLS #300392) and SW403 (CLS #300350) were obtained from 
the Cell Line Service culture collection (DKFZ, Heidelberg, Germany). SW480 and HCT116 
cell lines were obtained from the Max Planck Institute of Immunobiology and Epigenetics, 
Freiburg, Germany. Identity of the cell lines was confirmed by a multiplex human cell line 
authentication test (Multiplexion, Immenstaad, Germany). Cells were cultured as previously 
described [25]. To generate the stable Lef1-HA expression cell line, retroviral infection with 
pRetroX-tight-Pur-based vectors was used as described [23]. As recipients, LS174T cells 
stably transfected with the pN1pßactin-rtTA2S-M2-IRES-EGFP plasmid were used [36]. 
LS174T cells transduced with a Dox-inducible Snail1-HA retroviral vector were previously 
described [28]. To induce protein expression in stable cell lines, cells were treated with 0.1 
µg/ml Dox or 1 µg/ml Dox for the indicated time periods as described in the figure legends. 
 
 
2.6. Luciferase reporter assays 
 
For luciferase reporter assays, 1 x 105 LS174T, SW480 and HCT116 cells or 2 x 105 SW403 
cells per well were seeded in 24-well plates and transfected with the FuGENE6 reagent 
(Promega, Heidelberg, Germany) according to the manufacturer’s protocol. The cells 
received a mixture of 10 ng of the Renilla luciferase expression vector pRL-CMV (Promega, 
Heidelberg, Germany) and 250 ng of pGL3promoter plasmid containing the indicated EPHB2 
fragments. Cell lysates were prepared and reporter activity was determined 48 h after 
transfection as described [23]. Renilla luciferase activity was used for normalization. 
 
 
2.7. RNA isolation, cDNA synthesis and quantitative reverse transcriptase-PCR 
 
Total RNA was isolated using the peqGOLD total RNA Kit (PeqLab, Erlangen, Germany). 
Complementary DNA (cDNA) synthesis and reverse transcriptase (RT)-PCR were performed 
as previously described [23]. For cDNA synthesis, 500 ng of total RNA was used as template 
and oligo-dT oligonucleotides served as primers. Quantitative RT-PCR (qRT-PCR) was 
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performed with the CFX-96 multicolor real-time PCR detection system (BioRad, Munich, 
Germany) using SYBR green reaction mix (PeqLab, Erlangen, Germany). A cDNA amount 
equivalent to 20 ng of total RNA was used as template. Values shown represent expression 
of the genes-of-interest relative to GAPDH. Primers are listed in Table 1. 
 
 
2.8. Western blotting and immunodetection 
 
Protein expression levels of CDX2, FOXA1 and MYB were determined using nuclear 
extracts. For this, cells from three 15 cm dishes were used. After washing with ice-cold PBS, 
cells were collected, pooled, and transferred to 15 ml tubes. Cells were centrifuged at 500 x 
g and 4°C for 5 min. Then, the cell pellet was resuspended in a fivefold volume of hypotonic 
swelling buffer [10 mM Hepes/KOH pH 7.9, 0.75 mM spermidine, 0.15 mM spermin, 0.1 mM 
EDTA, 0.1 mM EGTA, 10 mM KCl, Complete protease inhibitor (Roche, Mannheim, 
Germany), 1 mM DTT, 0.5 mM PMSF] and incubated on ice for 10 min upon which cells 
were mechanically lysed by 15 strokes in a dounce homogenizer with tight-fitting pestle. 
Afterwards, 1 volume of sucrose restore buffer [8 volumes 75% (wt/vol) sucrose combined 
with 1 volume 10 x salt buffer (500 mM Hepes/KOH pH 7.9, 7.5 mM spermidine, 1.5 mM 
spermin, 2 mM EDTA, 1 mM EGTA, 100 mM KCl, Complete protease inhibitor, 1 mM DTT)] 
was added, and nuclei were pelleted by centrifugation at 4°C and 4,600 x g for 5 min. The 
supernatant was discarded, and the nuclei were resuspended in nuclei extraction buffer [20 
mM Hepes/KOH pH 7.9, 0.75 mM spermidine, 0.15 mM spermin, 0.2 mM EDTA, 0.1 mM 
EGTA, 25% (vol/vol) glycerin, 400 mM KCl, Complete protease inhibitor, 1 mM DTT, 0.5 mM 
PMSF] at 4°C for 30 min with constant gentle agitation. The nuclear extract was cleared by 
centrifugation at 110,000 x g and 4°C for 30 min and then stored at -80°C. For the detection 
of SNAIL1, EPHB2, TCF7L2 and LEF1 whole-cell lysates were prepared by lysing cells in 
IPN-150 (50 mM Tris/HCl pH 7.6, 150 mM NaCl, 5 mM MgCl2, 0.1% Nonidet P-40, Complete 
protease inhibitor, 1 mM DTT) for 30 min on ice. Thereafter, cell lysates were cleared by 
centrifugation at 16,000 x g and 4°C for 10 min. Protein concentration was determined using 
the DC Protein Detection Kit (BioRad, Munich, Germany). Proteins were separated by SDS-
polyacrylamide gel electrophoresis and transferred on nitrocellulose membranes. 
 
 For immunodetection, the following antibodies were used: Goat polyclonal anti-
EPHB2 (1:1,000, AF467; R&D Systems, Minneapolis, USA), mouse monoclonal anti-α-
TUBULIN (1:10,000, T9026; Sigma-Aldrich, St. Louis, USA), mouse monoclonal anti-GSK3β 
(1:1,000, 610201; BD Biosciences, Franklin Lakes, USA), rat monoclonal anti-HA (1:1,000, 
3F10; Roche, Mannheim, Germany), mouse monoclonal anti-LEF1 (1:1,000, sc-81470, 
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Santa Cruz, Heidelberg, Germany), rabbit monoclonal anti-TCF7L2 (1:1,000, 2565; Cell 
Signaling Technology, Cambridge, UK), goat polyclonal anti-FOXA1 (1:1,000, ab5089, 
Abcam, Cambridge, UK), rabbit monoclonal anti-v-MYB and c-MYB (1:1,000, ab45150, 
Abcam, Cambridge, UK), rabbit monoclonal anti-CDX2 (1:1,000, D11D10, Cell Signaling 
Technology, Cambridge, UK), rabbit polyclonal anti-POL2 (1:1,000, sc-899, Santa Cruz, 
Heidelberg, Germany), rabbit polyclonal anti-ZEB1 (1:2,000, HPA027524, Sigma-Aldrich, St. 
Louis, USA), rabbit monoclonal anti-SNAIL2 (1:1,000, 5% BSA, C19G7/#9585, Cell Signaling 
Technology, Cambridge, UK), rabbit monoclonal anti-Snail1 (1:1,000, 5% BSA, 
C15D3/#3879, Cell Signaling Technology, Cambridge, UK). Visualization of antibody:antigen 
complexes was performed as previously described [24]. 
 
 
2.9. Electrophoretic mobility shift assay (EMSA) 
 
EMSAs were used to study DNA binding of transcription factors to the EPHB2 minimal 
enhancer fragment in vitro. Proteins of interest were transcribed and translated in vitro using 
the TNT SP6 high-yield wheat-germ protein expression system with 2.5 µg of the plasmid 
DNA in 25 µl reactions at 25°C for 120 min (Promega, Heidelberg, Germany). Protein 
expression was confirmed by Western blot. DNA probes for EMSA were generated by PCR 
with biotinylated primers using wild type or mutated versions of the EPHB2 -8398/-8272 
enhancer subfragment as DNA template. Sequence information for the oligonucleotides used 
is given in Table 1. 10 fmol of the biotinylated probe were combined with equal amounts of 
the protein of interest, 60 µg of bovine serum albumin, 1 µg poly(dI:dC) and incubated in 
EMSA-buffer (20 mM Hepes/KOH pH 7.9, 75 mM NaCl, 2 mM MgCl2, Complete protease 
inhibitor, 1 mM DTT) for 30 min on ice (total volume: 20 µl). For the competitive EMSAs, only 
1 fMol of biotinylated probes were used. Binding reactions were loaded onto 6% (wt/vol) 
polyacrylamide gels with 0.5 x Tris-borate-EDTA running buffer to separate the complexes. 
For further processing, the chemiluminescent nucleic acid detection module (Thermo Fisher 
Scientific, Dreieich, Germany) was used according to the manufacturer’s protocol. 
 
 
2.10. Formaldehyde-assisted isolation of regulatory elements (FAIRE) 
 
FAIRE was used to enrich for nucleosome depleted DNA and was performed as previously 
described [2]. The cells used for the experiments were crosslinked with 1% formaldehyde for 
7 min or were left untreated as reference material. Sonification was performed with 300 µl 
aliquots of the sample for 20 cycles with 30 s on/30 s off (high amplitude) in a Bioruptor Plus 
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(Diagenode, Denville, USA) producing DNA fragments between 250 and 750 bp in length. 
For quantitative PCR (qPCR), 40 ng DNA was used that had been recovered from 
crosslinked cells and non-crosslinked reference material. Data calculation was conducted as 
previously described [23]. Primer sequences are listed in Table 1. 
 
2.11. Chromatin immunoprecipitation 
 
Chromatin immunoprecipitation (ChIP) was performed as described [2]. Briefly, cells were 
crosslinked with 1% formaldehyde, chromatin was isolated and sheared by sonication. For 
precipitations with the anti-HA antibody, 200 µg chromatin were used. In all other cases of 
antibodies 100 µg chromatin were used. The amounts of antibodies employed for ChIP were 
as follows: 1 µg of rabbit polyclonal anti-HA (ab9110; Abcam, Cambridge, UK), 2 µg of rabbit 
polyclonal anti-H3 (ab1791; Abcam, Cambridge, UK), 2 µg of rabbit polyclonal anti-H3K4me1 
(pAb-037–050; Diagenode, Denville, USA), 2 µg of rabbit polyclonal anti-H3K27ac (ab4729; 
Abcam, Cambridge, UK), 2 µg of goat polyclonal anti-TCF7L2 (N-20, sc-8631; Santa Cruz, 
Heidelberg, Germany), 2 µg of mouse monoclonal anti-LEF1 (sc-81470, Santa Cruz, 
Heidelberg, Germany), 3 µg of goat polyclonal anti-FOXA1 (ab5089, Abcam, Cambridge, 
UK), 2 µg of rabbit monoclonal anti-v-MYB and c-MYB (ab45150, Abcam, Cambridge, UK), 2 
µg of goat polyclonal anti-β-catenin (AF1329, R&D Systems, Minneapolis, USA). qPCR was 
performed as described above using 1 µl of precipitated DNA and 2% of the input material as 
template with primers listed in Table 1. Data were calculated as percent input relative to H3 
(H3K27ac, H3K4me1) or as percent input (transcription factor ChIPs). 
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3. Results 
 
3.1. Expression of Snail1-HA diminishes features of active chromatin at the EPHB2 -8.4 kb 
enhancer 
 
There is a statistically significant negative correlation between the expression of EPHB2 and 
the average expression of a gene set consisting of EMT inducers (including SNAI1) and 
markers of mesenchymal cells (FN1, VIM) in the transcriptomes of 290 colorectal tumor 
samples (GSE14333; Fig. S1A). A trend of anti-correlated expression in colorectal tumor 
samples and in a cohort of 155 CRC cell lines (GSE59857) can also de detected by the 
pairwise analysis of EPHB2 and SNAI1 expression levels (Fig. S1B). Typically, samples with 
high EPHB2 levels show low expression of SNAI1 and vice versa. The inverse relationship 
between EPHB2 and SNAI1 expression can also be seen at the mRNA and protein levels in 
the LS174T, SW480, HCT116 and SW403 CRC cell lines (Fig. S1C,D). Furthermore, Dox-
induced expression of mouse Snail1-HA in LS174T CRC cells leads to the downregulation of 
EPHB2 over a time period of 96 h (Fig. S1E,F). 
 
 Overall, these observations strongly suggest that EPHB2 is negatively regulated by 
SNAIL1 in CRC. On the other hand, we previously implicated a cell-type-specific enhancer 
element located at -8.4 kb upstream of the EPHB2 transcriptional start site (TSS) in the 
differential expression of EPHB2 in CRC cells [2]. However, it is not known whether this 
enhancer is the sole element involved in pathological EPHB2 silencing and whether the 
enhancer is targeted by SNAIL1. As a first step to address these questions we therefore 
performed bioinformatic analyses to systematically screen the EPHB2 5’-region for the 
presence of potential regulatory elements. Thereby, a large number of evolutionary 
conserved DNA sequence blocks were identified that could represent regulatory elements 
(Fig. 1A). To further pinpoint potential control elements we queried the ENCODE data base 
(http://genome.ucsc.edu/; Human Feb. 2009 (GRCh37/hg19) Assembly) as an additional 
source of information. This analysis indicated the occurrence of DNase I hypersensitive sites 
(DHS) in chromatin of HUVEC cells around -8.0 kb, -6.0 kb, and close to the TSS. The 
general enhancer mark H3K4me1 appeared to be enriched around -8.0 kb and -6.0 kb (Fig. 
1A). The ENCODE data furthermore suggested an enrichment of the histone modification 
H3K27ac that specifies active enhancers and promoter regions, around -8.0 kb and close to 
the TSS. In summary, the bioinformatic screen identified three candidate regulatory regions: 
the already known enhancer region, the region around -6.0 kb, and distal promoter elements. 
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 As a next step, we performed FAIRE experiments with CRC cell lines and scanned 
the EPHB2 5’-region for differences in chromatin structure that might be linked to differential 
EPHB2 expression (Fig. S2A,B). In agreement with the results described above, we 
observed an elevated FAIRE signal at -8.4 kb, -6.2 kb, and close to the TSS. However, only 
the -8.4 kb region showed a reduction of the FAIRE signal in SW480 and HCT116 cells 
where EPHB2 is not expressed. ChIP experiments further confirmed that EPHB2 expression 
states are reflected by differences in the association of the EPHB2 -8.4 kb region with 
histone H3, H3K4me1 and H3K27ac (Fig. S2C). Interestingly, when we analyzed the same 
chromatin features in LS174T cells with Dox-inducible expression of Snail1-HA before and 
after Dox treatment, we observed a clear shift from an active enhancer state to a more 
inactive conformation, as indicated by a diminished FAIRE signal around -8.4 kb. (Fig. 1B). 
No other statistically significant chromatin structural changes within the EPHB2 5’-region 
were observed. ChIP experiments with antibodies against H3 additionally confirmed a more 
condensed chromatin state of the EPHB2 -8.4 kb region upon Snail1-HA induction (Fig. 1C). 
Furthermore, the levels of the more general enhancer modification H3K4me1 seem to be 
reduced upon Snail1-HA as well. ChIP analyses also showed a clear reduction in the levels 
of the active enhancer mark H3K27ac (Fig. 1C). 
 
 We also performed luciferase reporter gene assays to functionally assess the 
regulatory potential of the EPHB2 -6.2 kb region. For comparison, constructs with the EPHB2 
-8.4 kb enhancer and a fragment that covers an extended block of evolutionary conserved 
sequences around -11 kb were included in the experiments (Fig. S3). The results of the 
reporter gene assays confirmed the cell-type-specific enhancer function of the EPHB2 -8.4 
kb region. In contrast, neither the -11 kb fragment nor the -6.2 kb region were able to 
stimulate or repress luciferase reporter activity in CRC cells that differ with respect to EPHB2 
expression (Fig. S3). Thus, the results obtained up to this point indicate that the cell-type-
specific enhancer at -8.4 kb within the EPHB2 locus that is active only in the EPHB2 
expressing CRC cell lines is also likely to be the target for decommissioning by the EMT 
inducer SNAIL1. 
 
 
3.2. EPHB2 enhancer activity depends on CDX2, TCF7L2, FOXA1 and MYB 
 
To learn more about the regulation of the EPHB2 -8.4 kb enhancer region, we sought to 
identify the smallest enhancer DNA fragment that still exhibited differential activity in CRC 
cell lines. Therefore, luciferase reporter assays with different fragments of the EPHB2 
enhancer region were performed in four CRC cell lines that differ in their EPHB2 expression 
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(Figs. 2 and S4). The longest fragment tested completely covered the described region with 
elevated levels of H3K4me1, H3K27ac and DHS (Figs. 2 and S4, fragment 1). The analysis 
of this fragment in luciferase reporter assays showed elevated luciferase expression only in 
LS174T cells and not in SW480, HCT116 and SW403. To narrow down the size of the 
enhancer, the fragment was further split into two overlapping subfragments (Figs. 2 and S4, 
fragments 2 and 3). Interestingly, both EPHB2 enhancer fragments 2 and 3 were able to 
increase luciferase expression in LS174T and SW403 CRC cell lines and not in SW480 and 
HCT116, thereby confirming the suggested cell-type-specificity of the EPHB2 enhancer 
fragment. The overlap of these two fragments exhibited the described cell-type-specificity as 
well (Figs. 2 and S4, fragment 4). Further reduction in fragment size showed that the 126 bp 
fragment 5 was also able to drive increased luciferase expression in LS174T and SW403 
CRC cell lines but not in SW480 and HCT116 cells at levels comparable to those of 
fragments 1-4 (Figs. 2 and S4, fragment 5). The 78 bp fragment 7 was also endowed with 
cell-type-specific enhancer activity but appeared to be somewhat less active than fragment 5, 
especially in LS174T cells (Figs. 2 and S4, fragment 7). In contrast, fragments 6 and 8 had a 
much reduced, albeit statistically significant potential to stimulate luciferase reporter activity 
(fragment 6: LS174T and SW403 cells; fragment 8: LS174T cells) and even exhibited some 
cell-type-specificity (Figs. 2 and S4). These findings led us to conclude that the minimal cell-
type-specific enhancer fragment of the EPHB2 -8.4 kb enhancer region can be confined to 
fragment 5, covering EPHB2 upstream sequences -8398/-8272. 
 
 Next, we aimed to identify potential binding sites for transcription factors within the 
EPHB2 minimal enhancer fragment -8398/-8272 using different online tools for transcription 
factor binding motif prediction [30, 31]. In combination with additional manual inspection, this 
led to the identification of putative binding sites for several transcription factors with well 
known roles in the development and maintenance of intestinal epithelial stem cells, namely 
CDX2, MYB, members of the TCF/LEF family, and members of the FOX transcription factor 
family (Fig. 3A) [37-41]. Single, discrete binding motifs for CDX2 and TCF/LEF proteins were 
predicted, however, single but overlapping FOX and MYB binding motifs were found. 
 
 As a first step towards testing the importance of these motifs for EPHB2 enhancer 
function, we performed EMSAs with recombinant CDX2, TCF7L2, FOXA1 and MYB using 
the EPHB2 fragment -8398/-8272 as probe. To demonstrate binding specificity, EMSAs with 
probes harboring mutated versions of the transcription factor binding motifs were performed 
in parallel (Fig. 3B). Both TCF7L2 and MYB formed a sole protein::DNA complex with the 
wild-type (WT) EPHB2 enhancer probe. These complexes completely disappeared when 
their presumptive binding sites were mutated (Figure 3B,C). Although the in silico analyses 
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had predicted only a single binding site each for CDX2 and FOXA1, both factors formed two 
DNA::protein complexes with the EPHB2 enhancer probe (Fig. 3C). This could be 
alternatively explained by the presence of additional, cryptic binding sites that could not be 
identified by the in silico search, or by the formation of protein multimers independently of the 
presence of a second binding site within the EPHB2 enhancer sequences. In support of the 
latter possibility we observed that mutation of the single predicted CDX2 binding motif 
nonetheless abolished formation of both CDX2::DNA complexes. Likewise, formation of both 
FOXA1::DNA complexes was simultaneously impaired when just the one predicted FOX 
binding site was mutated. Altogether we conclude that CDX2, TCF7L2, FOXA1, and MYB 
can specifically interact with EPHB2 enhancer sequences in vitro. 
 
 We were interested in the functional importance of the identified transcription factor 
binding sites. To this end we performed luciferase reporter assays with WT and mutated 
versions of the EPHB2 -8398/-8272 enhancer construct in LS174T cells. As expected, we 
observed a clear increase in luciferase expression in the presence of the WT enhancer 
sequences (Fig. 3D). Enhancer activity was reduced by 77% when the TCF/LEF binding site 
was mutated. Mutation of the CDX2 binding motif as well as mutation of the overlapping 
FOX/MYB sites decreased EPHB2 enhancer activity by 55% and 52%, respectively (Fig. 
3D). These results demonstrate that intact binding motifs for CDX2, TCF7L2, FOXA1, and 
MYB are required for EPHB2 enhancer functionality and suggest that these transcription 
factors constitute activators of the EPHB2 enhancer. Further support for a regulatory function 
of CDX2, TCF7L2, FOXA1, and MYB at the EPHB2 gene is provided by a statistically highly 
significant positive correlation between the expression levels of these factors and that of 
EPHB2 in the transcriptomes of colorectal tumors and CRC cell lines (Fig. S5A). However, 
because of the overlap of the FOXA1 and MYB binding sites, at this point it is not possible to 
tell whether both or only one of the factors contribute to EPHB2 enhancer activity. 
 
 
3.3. Snail1 inactivates the EPHB2 -8.4 kb enhancer by downregulation of its main activators 
 
We next investigated a potential link between the identified enhancer factors and the 
decommissioning of the EPHB2 -8.4 kb enhancer through SNAIL1. One possibility was that 
SNAIL1 targets CDX2, MYB, and FOXA1 to indirectly downregulate EPHB2. If so, one would 
expect that their expression parallels that of EPHB2 in our model of CRC cell lines. In fact, 
the abundance of the EPHB2 enhancer factors is reduced or absent in SW480 and HCT116 
cells that express endogenous SNAIL1 (Fig. S5B). Likewise, the expression of CDX2, 
FOXA1, and MYB was significantly decreased upon induction of Snail1-HA in LS174T cells, 
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both on the mRNA and protein level (Fig. 4A,B). The downregulation took place within the 
first 24 h of Dox treatment and expression levels of FOXA1 and MYB remained well below 
those of control cells thereafter. In contrast, CDX2 expression showed full recovery at later 
time points. To further examine the relationship between EPHB2 expression and the 
transcription factors CDX2, FOXA1, MYB, and TCF7L2 as well as the role of SNAIL1 in the 
regulation of these genes, we performed a pairwise correlation analysis based on the two 
microarray datasets GSE14333 and GSE59875 described above. The analysis showed that 
EPHB2 and its potential activators CDX2, FOXA1, and MYB formed a cluster of genes 
whose expression was mainly positively correlated among each other (Fig. 4C). Similarly, the 
EMT-inducers SNAI1, SNAI2, and ZEB1 formed a distinct cluster of genes which were 
positively correlated among each other. Intriguingly, the expression of the genes in the two 
described clusters was clearly anti-correlated. The described results could be observed in 
both datasets, in the colorectal tumor samples and in the CRC cell lines, underlining the 
generality of this observation. The association of TCF7L2 with either of the two anti-
correlated expression clusters was less obvious since its expression only positively 
correlated with FOXA1 in both datasets. 
 
 We then performed ChIP experiments to investigate the occupancy of CDX2, FOXA1, 
and MYB at the EPHB2 -8.4 kb enhancer region in vivo and to analyze the effects of the 
induction of Snail1-HA on the binding of these factors (Fig. 4D). In control cells and in the 
absence of Snail1-HA, all three transcription factors showed a clear enrichment at the 
EPHB2 enhancer region at -8.4 kb compared to a negative control region at -12.3 kb. 
Furthermore, the induction of Snail1-HA led to a strong decrease in enhancer occupancy for 
FOXA1 and MYB within 48 h of Dox treatment. However, no significant reduction in CDX2 
enrichment was observed upon Snail1-HA expression. From these observations we conclude 
that the Snail1-HA-induced silencing of EPHB2 expression involves the downregulation of 
MYB and FOXA1 and thereby their displacement from the EPHB2 -8.4 kb enhancer region.  
 
 The observed anti-correlation between EPHB2, CDX2, FOXA1, and MYB on the one 
hand, and the EMT inducers SNAI1, SNAI2 and ZEB1 on the other hand, prompted us to 
investigate whether other EMT inducers might also be able to repress EPHB2. For this we 
generated LS174T cells that allowed for Dox-inducible expression of ZEB1-HA and SNAIL2-
HA. However, neither ZEB1-HA nor SNAIL2-HA expression led to the downregulation of 
EPHB2 (Fig. S6). Interestingly, ZEB1-HA and SNAIL2-HA also failed to repress or otherwise 
deregulate FOXA1, MYB and CDX2 (Fig. S6), thereby additionally pointing towards the 
importance of MYB and FOXA1 downregulation for EPHB2 enhancer decommissioning. 
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Thus, SNAIL1 appears to be unique in its ability to repress EPHB2 expression, most likely 
because of its distinctive pleiotropic effects. 
 
3.4 Snail1-HA expression induces a TCF7L2/LEF1 switch at the EPHB2 -8.4 kb enhancer 
 
EPHB2 is a known Wnt/β-catenin-regulated gene and binding experiments in vitro as well as 
luciferase reporter assays suggested a role for TCF7L2 and the TCF/LEF motif within the 
EPHB2 fragment -8398/-8272 for the regulation of EPHB2 expression. However, in contrast 
to the expression levels of CDX2, FOXA1, and MYB, no changes in the levels of TCF7L2 
were observed upon the induction of Snail1-HA in LS174T cells (Fig. 5A,B). Interestingly, the 
expression of LEF1, another member of the TCF/LEF family of transcription factors, was 
strongly up-regulated by Snail1-HA on the mRNA as well as on the protein level (Fig. 5A,B). 
Notably, the induction of LEF1 expression again was a specific feature of Snail1-HA and 
could not be observed at comparable levels in LS174T-SNAIL2-HA and LS174T-ZEB1-HA 
cells (Fig. S6). 
 
 To investigate the possible binding of LEF1 to the TCF/LEF motif within the minimal 
enhancer fragment of EPHB2, an in vitro binding experiment was performed. Indeed, like 
TCF7L2, recombinant LEF1 was able to bind to the TCF/LEF motif within the EPHB2 
fragment -8398/-8272 and binding was abolished when the TCF/LEF motif was mutated (Fig. 
5C, lanes 3 and 4). Intriguingly, under competitive conditions, the affinity of LEF1 to the 
TCF/LEF motif was higher than the affinity of TCF7L2 (Fig. 5C, lane 5). This in vitro binding 
result was confirmed by ChIP analyses with living cells (Fig. 5D). Upon the induction of 
Snail1-HA in LS174T cells the occupancy of TCF7L2 at the EPHB2 -8.4 kb enhancer region 
decreased while in parallel an enrichment of LEF1 at the same position was observed. 
Apparently, upon expression of Snail1-HA, a switch occurs in occupancy of the EPHB2 8.4kb 
enhancer region from TCF7L2 to LEF1. 
 
 To determine whether this switch in occupancy might have any consequences for 
EPHB2 -8.4 kb enhancer function, we performed luciferase reporter gene assays. Different 
combinations of expression vectors for TCF7L2, LEF1 and a constitutively active form of β-
catenin were cotransfected into LS174T cells together with a reporter plasmid containing the 
EPHB2 minimal enhancer fragment. Reporter constructs harboring a mutation in the 
TCF/LEF binding site of the EPHB2 minimal enhancer and carrying no EPHB2 enhancer 
sequences at all served as controls. Although these experiments revealed a non-specific 
stimulatory effect of TCF7L2 and LEF1 overexpression on the promoter-only reporter 
construct, we did not observe functional differences between TCF7L2 and LEF1 in this 
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setting (Fig. S7). In contrast, in the presence of the wild-type EPHB2 minimal enhancer we 
found that the combination of β-catenin and TCF7L2 significantly stimulated whereas 
coexpression of β-catenin and LEF1 reduced EPHB2 minimal enhancer activity (Fig. S7). As 
expected, mutation of the TCF/LEF binding motif at the EPHB2 minimal enhancer decreased 
reporter gene expression and largely leveled differences between TCF7L2 and LEF1. 
Especially, the mutation abolished the ability of β-catenin to modulate TCF7L2 and LEF1 
activity. This lends support to the specificity of the opposing effects that TCF7L2 and LEF1 
had at the wild-type EPHB2 minimal enhancer in the presence of β-catenin, and argues that 
LEF1 has a repressive effect on EPHB2 minimal enhancer activity. Therefore, in addition to 
the downregulation of FOXA1 and MYB, the TCF7L2/LEF1 switch may also contribute to the 
decommissioning of the EPHB2 -8.4 kb enhancer region in the wake of Snail1-HA induction. 
 
 
3.5 The Lef1-HA/TCF7L2 exchange does not suffice to disrupt the EPHB2 -8.4 kb enhancer 
complex and to permanently downregulate EPHB2 
 
Snail1 appears to disable the EPHB2 -8.4 kb enhancer by simultaneously displacing or 
exchanging multiple transcription factors. However, the enhanceosome model for 
transcriptional enhancers suggests that the dysfunction of a single transcription factor would 
suffice to completely deactivate an enhancer [42]. Therefore, we were curious to see how a 
single change in transcription factor composition of the EPHB2 -8.4 kb enhancer would affect 
EPHB2 expression. To this end, we generated LS174T cells that upon Dox treatment 
express Lef1-HA. Upon induction of Lef1-HA for 24 h, expression of EPHB2 was significantly 
downregulated on the mRNA and on the protein level (Fig. 6A,B). Interestingly, at later time 
points EPHB2 expression fully recovered. Furthermore, expression analyses for CDX2, 
FOXA1, and MYB revealed clear differences between cells overexpressing Lef1-HA and 
Snail1-HA. While Snail1-HA induction had strongly downregulated FOXA1 and MYB, mRNA 
levels of MYB hardly changed upon expression of Lef1-HA (Fig. 6A) and the observed 
alterations in MYB protein amounts were not specific for Lef1-HA expressing cells (Fig. 6B). 
In contrast to what had been observed in Snail1-HA expressing cells, FOXA1 transcript and 
protein levels actually increased in Lef1-HA expressing cells (Fig. 6A,B). Likewise, Snail1-HA 
had provoked a temporary but pronounced decrease in CDX2 expression whereas the 
transient decrease in CDX2 transcript quantity was much less extensive in the presence of 
Lef1-HA (Fig. 6A). The temporary decline in CDX2 protein amounts, however, appeared 
comparable in Snail1-HA and Lef1-HA expressing cells (compare Figs. 4B and 6B). 
Moreover, there was no reciprocal induction of SNAI1 expression in the presence of Lef1-
HA. 
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 Next, we wished to determine whether the transient downregulation of EPHB2 upon 
expression of Lef1-HA was accompanied by any change in transcription factor occupancy 
and chromatin structure at the EPHB2 -8.4 kb enhancer. To gain insight into this aspect, we 
conducted ChIP and FAIRE analyses. As it had already been seen following the expression 
of Snail1-HA, a switch between TCF7L2 and Lef1-HA at the EPHB2 -8.4 kb enhancer was 
observed (Fig. 6C). Furthermore, at 24 h post-induction of Lef1-HA, levels of the active 
enhancer mark H3K27ac were decreased in the presence of Lef1-HA (Fig. S8A). This is in 
agreement with reduced EPHB2 transcriptional activity at this time point. In contrast, the 
occupancy of the EPHB2 -8.4 kb enhancer by FOXA1, MYB, and CDX2 was not altered in 
Lef1-HA expressing cells (Fig. 6D). We also investigated whether the TCF7L2/Lef1-HA 
exchange affected the interaction of β-catenin with the EPHB2 -8.4 kb enhancer. β-Catenin 
was present at the EPHB2 -8.4 kb enhancer in control cells and prior to Lef1-HA induction 
(Fig. S8C). β-Catenin also occupied the enhancer at the 6 h, 24 h and 48 h time points of 
Lef1-HA expression (Fig. S8C). Likewise, the open chromatin structure at the EPHB2 -8.4 kb 
enhancer as indicated by an elevated FAIRE signal and low abundance of H3 remained 
unchanged despite Lef1-HA occupancy (Fig. S8A,B). Apparently, the Lef1-HA/TCF7L2 
exchange does not suffice to disrupt the EPHB2 -8.4 kb enhancer complex. Nonetheless, 
these results suggest that the temporary downregulation of EPHB2 upon Lef1-HA induction 
might be caused by the switch between TCF7L2 and Lef1-HA. A permanent decrease of 
EPHB2 expression, however, seems to be prevented by the continuous occupancy of the 
EPHB2 -8.4 kb enhancer by CDX2, FOXA1, MYB and β-catenin. 
 
 Finally, we examined whether the expression of LEF1 and EPHB2 is negatively 
correlated similar to what we had seen for EPHB2 and SNAI1. However, there is only a 
marginal and statistically insignificant anti-correlation between EPHB2 and LEF1 expression 
in the transcriptomes of CRC cell lines and tumors (Fig. S5C). This could be explained by the 
fact that LEF1 is not an exclusive target of SNAIL1 and obviously multiple changes in 
transcription factor expression are needed to inactivate the EPHB2 -8.4 kb enhancer. 
Therefore, SNAIL1-independent upregulation of LEF1 in some CRC cell lines and tumors 
would not be expected to concur with reduced EPHB2 levels without the concomitant loss of 
MYB and FOXA1 expression that we observed to be deregulated by SNAIL1 but not LEF1. 
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4. Discussion 
 
EPHB2 is an important tumor suppressor gene whose expression is secondarily 
downregulated during the transition from the non-invasive adenoma to the invasive 
carcinoma state in a sizable fraction of colorectal cancers [15, 25, 26]. The aim of the present 
study was to gain insights into the mechanisms that lead to the silencing of EPHB2 during 
CRC progression, with a special interest in the roles that the EPHB2 -8.4 kb enhancer and 
the EMT-inducer SNAIL1 play in this process. Indeed, Snail1-induced repression of EPHB2 
appears to result from the decommissioning of the EPHB2 -8.4 kb enhancer. However, 
Snail1 does not seem to directly act upon this regulatory element. Rather, it inactivates the 
EPHB2 -8.4 kb enhancer through the downregulation of FOXA1 and MYB, thereby displacing 
two activating transcription factors from the enhancer. In addition, Snail1 upregulates LEF1 
which in turn replaces TCF7L2 at the EPHB2 -8.4 kb enhancer region. These changes in 
transcription factor occupancy are accompanied by a loss of structural hallmarks of active 
chromatin and lead to the decommissioning of the EPHB2 -8.4 kb enhancer region and 
EPHB2 transcriptional silencing. 
 
 
4.1. Indirect regulation of EPHB2 by Snail1 and role of the EPHB2 -8.4 kb enhancer 
 
There is an anti-correlation between EPHB2 and SNAI1 expression in the transcriptomes of 
CRC cell lines and tumors, and the induction of Snail1 in LS174T cells leads to a massive 
downregulation of EPHB2 (this study; [28]). In this regard there is considerable similarity 
between EPHB2 and the closely related EPHB3 gene [28]. However, in contrast to EPHB3 
which is directly repressed by Snail1, we believe that Snail1 inhibits EPHB2 expression 
through an indirect mechanism. This is because downregulation of EPHB2 is delayed 
compared to the direct Snail1 target genes EPHB3 and CDH1 [28]. Moreover, we have not 
yet been able to demonstrate an interaction of Snail1 with EPHB2 sequences by EMSA and 
ChIP (data not shown). 
 
 Through bioinformatic and chromatin structural analyses we aimed to identify cis-
regulatory elements involved in the downregulation of EPHB2 expression. Previous work 
from our laboratory had suggested that the EPHB2 -8.4 kb enhancer could be involved in the 
differential EPHB2 expression in a panel of CRC cells but at that time we did not identify 
relevant transcription factors and therefore the connections between EPHB2 downregulation, 
the EPHB2 -8.4 kb enhancer, and EMT remained unknown [2, 28]. We now show that within 
-12.3 kb of EPHB2 upstream sequences, the loss of active chromatin features in EPHB2 
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non-expressing cell lines occurs exclusively at the -8.4 kb region. Likewise, induction of 
Snail1 in LS174T cells causes changes in chromatin accessibility and histone-modifications 
around the EPHB2 -8.4 kb enhancer but not at other potential regulatory elements in the 5’-
region of EPHB2. Therefore, the EPHB2 -8.4 kb enhancer indeed appears to be intimately 
connected to Snail1-mediated repression of EPHB2. 
 
 The results from the chromatin structural analyses were complemented by luciferase 
reporter experiments. Our mapping studies identified the EPHB2 DNA sequences from -8398 
to -8272 as the smallest fragment that has enhancer activity in luciferase assays with CRC 
cell lines. Importantly, the EPHB2 minimal enhancer fragment exhibits cell-type-specificity 
that exactly parallels expression of the endogenous EPHB2 gene. This further supports the 
idea that the EPHB2 enhancer plays a key role in controlling EPHB2 expression and that 
inactivation of the enhancer underlies EPHB2 silencing. 
 
 The EPHB2 minimal enhancer fragment is located within one of the ECRs in the 
EPHB2 upstream region. Interestingly, the position of this ECR and the EPHB2 minimal 
enhancer fragment do not exactly match a region that shows DNaseI hypersensitivity and 
high levels of H3K4me1 and H3K27ac. This apparent discrepancy could be explained by the 
observation that enhancer core regions are usually devoid of histones. Therefore, histone 
modifications can be identified only in regions flanking enhancer cores [43]. It should also be 
kept in mind that the ENCODE data for DNaseI hypersensitivity and the enrichment of 
H3K4me1 and H3K27ac at the EPHB2 locus were derived from HUVEC cells. There are 
three ECRs between -9.0 kb and -7.5 kb upstream of the EPHB2 TSS. It is possible that 
these ECRs represent a cluster of regulatory elements that either individually or in 
combination control EPHB2 expression in different tissues. Accordingly, the EPHB2 -8.4 kb 
region could represent an intestine-specific regulatory element whereas EPHB2 expression 
in HUVEC cells might be driven by an adjacent, more promoter-proximal element. 
 
 
4.2. Transcription factors required for EPHB2 enhancer function 
 
In silico analyses identified a cluster of transcription factor binding sites within the EPHB2 
minimal enhancer fragment. By EMSA and ChIP we confirmed that CDX2, FOXA1, MYB, 
and TCF7L2 bind to the EPHB2 minimal enhancer region in vitro and in EPHB2 expressing 
cells. Our findings agree with the results of earlier studies that demonstrated the occupancy 
of the EPHB2 enhancer region by TCF7L2 and CDX2 [2, 44, 45] but the interaction of 
FOXA1 and MYB with this element was not previously known. In functional assays, mutation 
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of the CDX2, FOX/MYB, and TCF/LEF binding motifs led to a loss of enhancer activity. 
These novel findings provide strong evidence that CDX2, FOXA1, MYB, and TCF7L2 are 
important components of the EPHB2 enhancer transcription factor complex and function as 
transcriptional activators of the EPHB2 gene. However, we cannot rule out that additional 
transcription factors are involved in the regulation and maintenance of EPHB2 enhancer 
function because our analyses concentrated on the EPHB2 minimal enhancer. This was 
motivated by the cell-type-specific activity pattern of this element which reflects the 
expression of the endogenous EPHB2 gene. Nonetheless, as DNA sequence conservation 
and regions characterized by DNaseI hypersensitivity and H3K4me1/H3K27ac enrichment 
extend beyond the EPHB2 minimal enhancer, further transcription factors may contribute to 
the activity of the native EPHB2 enhancer in its chromosomal context. 
 
 In our DNA binding experiments in vitro we observed that CDX2 formed two distinct 
protein::DNA complexes although only a single CDX2 consensus binding motif within the 
EPHB2 minimal enhancer had been predicted. Both CDX2::DNA complexes completely 
disappeared when the single predicted CDX2 binding site was mutated. This implies that 
formation of the more slowly migrating CDX2::DNA complex critically depends upon CDX2 
self-interactions. In support of this idea, it was previously demonstrated that CDX2 has the 
capability of forming dimers [46]. Because CDX2 dimerization appears to be aided by the 
presence of variably spaced palindromic binding motifs [46], it cannot be ruled out that 
formation of CDX2 dimers at the EPHB2 minimal enhancer is supported to some extent 
through additional DNA contacts of CDX2 with cryptic binding sites. 
 
 Similar to CDX2, FOXA1 also generated two DNA complexes in EMSA analyses. In 
contrast to CDX2, however, formation of multiple FOXA1::DNA complexes probably is not 
due to dimerization [47, 48] but instead results from the presence of multiple FOXA1 binding 
motifs within the EPHB2 minimal enhancer fragment. In agreement with this idea, only one of 
the two FOXA1::DNA complexes completely disappeared while the other one was diminished 
when the mutated probe was used. Binding sites for members of the family of Forkhead 
domain DNA binding proteins are known to exhibit a fairly high degree of degeneracy [47], 
which could explain the difficulty of reliably detecting FOXA1 binding motifs by in silico 
analysis. 
 
 Curiously, the FOXA1 binding site that we identified and that was confirmed by EMSA 
and mutagenesis overlaps with a validated binding motif for the MYB transcription factor. In 
addition, ChIP analyses demonstrated occupancy of the EPHB2 enhancer by both factors in 
LS174T cells. This raises the question of how FOXA1 and MYB function at the EPHB2 
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enhancer. One possibility is that there are different cell populations in which FOXA1 and 
MYB alternatively occupy the EPHB2 enhancer. On the other hand, FOXA1 and MYB might 
simultaneously interact with the EPHB2 enhancer by virtue of distinct modes of DNA 
recognition [48, 49]. The co-occurrence of FOXA1 and MYB motifs and the cooperation 
between FOXA1 and MYB in chromatin binding at enhancer regions was previously 
described [50] and the overlapping FOXA1/MYB motifs at the EPHB2 enhancer could 
provide an example for the recently described phenomenon of unconventional composite 
DNA binding sites that form the basis for heterotypic transcription factor cooperations [51]. 
 
 CDX2, FOXA1, MYB, and TCF7L2 are transcription factors with well described 
functions in intestinal development and tissue homeostasis. CDX2 is a homeobox 
transcription factor with important roles in anterior-posterior patterning of the gastro-intestinal 
tract as well as control of gene expression along the crypt-villus axis [40, 52-54]. FOX 
proteins, including FOXA1, are involved in the specification and patterning of endoderm and 
its derivatives, and a contribution of FOXA1 to the differentiation of enteroendocrine and 
goblet cells has previously been shown [41, 55]. MYB is a proto-oncogene that was shown to 
control the self-renewal capacity of intestinal stem cells, most likely by regulating the 
expression of critical stem cell genes such as LGR5 [37]. Of note, like LGR5, EPHB2 is part 
of the intestinal stem cell signature [56]. TCF7L2 belongs to the TCF/LEF family of 
transcription factors which are well described mediators of the Wnt/β-catenin signaling 
pathway. Wnt/β-catenin signaling and TCF7L2 are required for the maintenance of the 
intestinal stem cell compartment [38] and EPHB2 was reported to be a Wnt/β-catenin target 
gene [12]. Altogether, in view of their known roles in the development and tissue 
homeostasis of the intestinal epithelium it is quite plausible that CDX2, FOXA1, MYB, and 
TCF7L2 converge on the EPHB2 -8.4 kb enhancer to collectively control EPHB2 expression. 
 
 
4.3. Enhancer inactivation through Snail1 
 
How does Snail1 incapacitate the EPHB2 -8.4 kb enhancer? Our results suggest that the 
induction of Snail1 in LS174T cells triggers multiple changes in gene expression and 
transcription factor occupancy that culminate in the decommissioning of the EPHB2 -8.4 kb 
enhancer (Fig. 6E). For one, FOXA1 and MYB are downregulated in the presence of Snail1. 
This leads to a strong reduction of FOXA1 and MYB occupancy at the EPHB2 -8.4 kb 
enhancer which thereby is deprived of two of its activators. Moreover, LEF1 is upregulated 
by Snail1 and competitively displaces TCF7L2 from the EPHB2 -8.4 kb enhancer. LEF1 has 
a higher affinity for TCF/LEF binding sites compared to TCF7L2, not only at the EPHB2 -8.4 
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kb enhancer but also at other target genes [34, 57]. This is likely to facilitate the 
TCF7L2/LEF1 exchange once LEF1 levels rise. It is conceivable that the replacement of 
TCF7L2 by LEF1 affects EPHB2 -8.4 kb enhancer function since TCF7L2 and LEF1 are 
functionally distinct [34, 58, 59], and LEF1 overexpression had a repressive effect on EPHB2 
minimal enhancer activity in luciferase reporter assays. Intriguingly, repressor functions of 
LEF1 in colorectal cancer cells [60] and at the CDH1 gene are known [61]. Hence, the 
exchange of two functionally distinct TCF/LEF family members may very well disconnect the 
EPHB2 -8.4 kb enhancer from the Wnt/β-catenin pathway. The continuous occupancy of the 
EPHB2 -8.4 kb enhancer by β-catenin despite the TCF7L2/LEF1 exchange is not necessarily 
in conflict with this view because there are precedents for the presence of β-catenin at genes 
that are negatively regulated by Wnt/β-catenin signaling [61, 62]. Ultimately, the combined 
loss of several activators probably in conjunction with some of their associated co-factors in 
turn might cause the observed reduction in H3K27ac levels and an increase in H3 
occupancy. 
 
 In contrast to FOXA1 and MYB, the expression of CDX2 is only transiently 
downregulated by Snail1, and CDX2 appears to remain associated with the EPHB2 -8.4 kb 
enhancer upon Snail1 induction. The continuous occupancy by CDX2 could be the reason 
for the incomplete collapse of EPHB2 -8.4 kb enhancer chromatin upon Snail1 induction 
which we observed in our FAIRE analyses. The additional loss of CDX2 expression as seen 
in HCT116 and SW480 [63] cells might explain the more complete chromatin compaction at 
the EPHB2 -8.4 kb enhancer in these cells. 
 
 The model for EPHB2 transcriptional silencing and the pathophysiological relevance 
of the regulatory relationships among SNAIL1, LEF1, CDX2, FOXA1, MYB, and EPHB2 are 
supported by several additional observations. In contrast to Snail1, two other well-
characterized EMT transcription factors SNAIL2 and ZEB1 did not repress EPHB2. 
Intriguingly, SNAIL2 and ZEB1 also failed to downregulate FOXA1, MYB and CDX2 and only 
weakly stimulated LEF1 expression. These findings are in agreement with the proposed 
model for EPHB2 repression that postulates the necessity for multiple concurrent changes in 
transcription factor expression and EPHB2 -8.4 kb enhancer occupancy. Furthermore, 
transcriptome analysis revealed an anti-correlated expression of SNAIL1 on the one hand, 
and of CDX2, MYB, FOXA1, and EPHB2 on the other hand in a broad range of CRC cell 
lines and a large number of tumors. In agreement with upregulation of LEF1 in LS174T cells 
downstream of Snail1, it has been observed that LEF1 is also induced during EMT in other 
model systems [64-66]. This regulation of LEF1 appears to occur indirectly and likely 
involves a cascade of gene expression changes which ultimately trigger LEF1 induction 
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through the activation of SMAD proteins [65]. SMADs can be activated by TGFβ and BMP 
signaling pathways both of which are known to positively regulate LEF1 [65, 67]. Importantly, 
LS174T cells are SMAD4-positive, have a functional BMP pathway [68] and BMP2 and 
BMP4 are upregulated in the presence of Snail1-HA (Fig. S9). Taken together, these 
observations provide strong evidence that Snail1-HA indirectly induces LEF1 expression 
through a BMP/SMAD axis. Furthermore, with respect to the other transcription factors 
involved in the regulation of EPHB2 expression and their role in tumor progression and EMT, 
it was shown that RNAi-mediated silencing of FOXA1 and FOXA2 is sufficient to induce EMT 
by downregulation of epithelial markers, such as CDH1, and it was argued that FOXA1 
exerts a so called roadblock function in EMT [69]. Like EPHB2, CDX2 functions as tumor 
suppressor in CRC and CDX2 expression is frequently lost during tumor progression. The 
role of MYB, however, is somewhat ambiguous. MYB was reported to promote EMT in 
different human cancer cells by the upregulation of SNAI2 [70], but MYB itself is rapidly 
downregulated in a breast cancer model of Snail1-induced EMT and MYB appears to be a 
direct target of ZEB1 in this context [71, 72]. Furthermore, several studies demonstrate a 
better prognosis and reduced metastasis in breast cancers with high expression of MYB [73]. 
Downregulation by EMT inducers and potential anti-metastatic activity would be consistent 
with the proposed role of MYB as an activator of a tumor and invasion suppressor gene such 
as EPHB2. 
  
 When compared to Snail1, overexpression of Lef1 and replacement of TCF7L2 by 
Lef1 at the EPHB2 -8.4 kb enhancer without concomitant downregulation of FOXA1 and 
MYB only had a mild effect on EPHB2 expression and did not suffice to repress EPHB2 for 
an extended period of time. The drop in EPHB2 expression was reflected by a decrease in 
the levels of H3K27ac, a chromatin mark that specifies active enhancers. Aside from that, 
EPHB2 -8.4 kb enhancer chromatin remained in an open conformation and CDX2, FOXA1, 
MYB, and β-catenin continued to occupy the EPHB2 -8.4 kb enhancer. Overall, these 
findings are in conflict with the enhanceosome model for enhancer function that proposes a 
high degree of cooperation between different enhancer-bound transcription factors. 
Accordingly, the lack of just one of these factors should be sufficient to impair enhancer 
function by disrupting the enhanceosome [42]. However, mutational analyses of the EPHB2 -
8.4 kb enhancer by luciferase reporter assays showed that the mutation of single 
transcription factor binding sites did not completely abolish enhancer activity. This result also 
argues that transcription factors can associate with the EPHB2 -8.4 kb enhancer largely 
independently from each other and thereby support partial enhancer function. Likewise, 
CDX2 remained at the EPHB2 -8.4 kb enhancer even upon dissociation of FOXA1, MYB, 
and TCF7L2. It seems as though the EPHB2 -8.4 kb enhancer adheres to the billboard 
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model for enhancer function. This model describes each enhancer factor or small group of 
factors as an independently acting unit and postulates that the loss of one of these units has 
only minor effects on the overall enhancer function [74]. Irrespective of which type of model 
applies to the EPHB2 -8.4 kb enhancer, it is nonetheless conceivable that the removal of 
only one component is not sufficient to dismantle huge, multi-component protein complexes 
that are formed by transcription factors together with their co-activators. In support of this 
view, it was recently described that EMT-associated repression of CDH1 also requires 
multiple assaults including the direct binding of Snail1 to the CDH1 promoter and the 
inactivation of two transcriptional enhancers by downregulation of Grhl3 and Hnf4α [75]. 
Similarly, inactivation of the EPHB3 enhancer is a multimodal process that involves the 
repression and competitive displacement of transcriptional activators by Snail1 [28]. 
 
 Enhancers are of utmost importance for the spatiotemporal orchestration of gene 
expression patterns for instance in development, adult life, cellular reprogramming, or 
tumorigenesis. Much work is dedicated to the understanding of enhancer activation during 
development and to mechanisms of enhancer action. In contrast, surprisingly little is known 
about the inactivation of enhancers although this process contributes essentially to the 
reshaping of gene expression programs. In fact, during tumor progression, the loss of active 
enhancers prevails over the gain of functional enhancers [76-78], and many fibroblast-
specific enhancers are decommissioned in the earliest phases of reprogramming [79]. The 
deregulation of multiple factors and combinatorial attacks on enhancer and/or promoter 
transcriptional complexes could be a more common mechanism to effectively silence gene 
expression. 
 
Acknowledgements 
We are grateful to K.-H. Klempnauer, M. Stemmler, T. Brummer and the BIOSS Toolbox for 
the gift of plasmids, K. Geiger for excellent technical assistance, and L. Münke for helpful 
comments and critical reading of the manuscript. This work was supported by a grant from 
the Deutsche Forschungsgemeinschaft (DFG CRC-850 subproject B5 to A. H.). 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
28 
References 
 
 
[1] T.K. Kim, R. Shiekhattar, Architectural and Functional Commonalities between Enhancers 
and Promoters, Cell, 162 (2015) 948-959. 
[2] S. Jägle, K. Rönsch, S. Timme, H. Andrlová, M. Bertrand, M. Jäger, A. Proske, M. 
Schrempp, A. Yousaf, T. Michoel, R. Zeiser, M. Werner, S. Lassmann, A. Hecht, 
Silencing of the EPHB3 tumor-suppressor gene in human colorectal cancer through 
decommissioning of a transcriptional enhancer, Proc Natl Acad Sci USA, 111 (2014) 
4886-4891. 
[3] L. Pasquali, K.J. Gaulton, S.A. Rodriguez-Segui, L. Mularoni, I. Miguel-Escalada, I. 
Akerman, J.J. Tena, I. Moran, C. Gomez-Marin, M. van de Bunt, J. Ponsa-Cobas, N. 
Castro, T. Nammo, I. Cebola, J. Garcia-Hurtado, M.A. Maestro, F. Pattou, L. Piemonti, 
T. Berney, A.L. Gloyn, P. Ravassard, J.L. Gomez-Skarmeta, F. Muller, M.I. McCarthy, J. 
Ferrer, Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated 
variants, Nat Genetics, 46 (2014) 136-143. 
[4] M.R. Mansour, B.J. Abraham, L. Anders, A. Berezovskaya, A. Gutierrez, A.D. Durbin, J. 
Etchin, L. Lawton, S.E. Sallan, L.B. Silverman, M.L. Loh, S.P. Hunger, T. Sanda, R.A. 
Young, A.T. Look, Oncogene regulation. An oncogenic super-enhancer formed through 
somatic mutation of a noncoding intergenic element, Science, 346 (2014) 1373-1377. 
[5] R.C. Poulos, M.A. Sloane, L.B. Hesson, J.W. Wong, The search for cis-regulatory driver 
mutations in cancer genomes, Oncotarget, 6 (2015) 32509-32525. 
[6] R. Kalluri, R.A. Weinberg, The basics of epithelial-mesenchymal transition, J Clin Inv, 119 
(2009) 1420-1428. 
[7] S. Lamouille, J. Xu, R. Derynck, Molecular mechanisms of epithelial-mesenchymal 
transition, Nat Rev Mol Cell Biol, 15 (2014) 178-196. 
[8] K.R. Fischer, A. Durrans, S. Lee, J. Sheng, F. Li, S.T. Wong, H. Choi, T. El Rayes, S. 
Ryu, J. Troeger, R.F. Schwabe, L.T. Vahdat, N.K. Altorki, V. Mittal, D. Gao, Epithelial-to-
mesenchymal transition is not required for lung metastasis but contributes to 
chemoresistance, Nature, 527 (2015) 472-476. 
[9] W.L. Hwang, J.K. Jiang, S.H. Yang, T.S. Huang, H.Y. Lan, H.W. Teng, C.Y. Yang, Y.P. 
Tsai, C.H. Lin, H.W. Wang, M.H. Yang, MicroRNA-146a directs the symmetric division of 
Snail-dominant colorectal cancer stem cells, Nat Cell Biol, 16 (2014) 268-280. 
[10] P. Zhang, Y. Wei, L. Wang, B.G. Debeb, Y. Yuan, J. Zhang, J. Yuan, M. Wang, D. Chen, 
Y. Sun, W.A. Woodward, Y. Liu, D.C. Dean, H. Liang, Y. Hu, K.K. Ang, M.C. Hung, J. 
Chen, L. Ma, ATM-mediated stabilization of ZEB1 promotes DNA damage response and 
radioresistance through CHK1, Nat Cell Biol, 16 (2014) 864-875. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
29 
[11] X. Zheng, J.L. Carstens, J. Kim, M. Scheible, J. Kaye, H. Sugimoto, C.C. Wu, V.S. 
LeBleu, R. Kalluri, Epithelial-to-mesenchymal transition is dispensable for metastasis but 
induces chemoresistance in pancreatic cancer, Nature, 527 (2015) 525-530. 
[12] E. Batlle, J.T. Henderson, H. Beghtel, M.M. van den Born, E. Sancho, G. Huls, J. 
Meeldijk, J. Robertson, M. van de Wetering, T. Pawson, H. Clevers, Beta-catenin and 
TCF mediate cell positioning in the intestinal epithelium by controlling the expression of 
EphB/ephrinB, Cell, 111 (2002) 251-263. 
[13] A. Merlos-Suarez, E. Batlle, Eph-ephrin signalling in adult tissues and cancer, Curr Opin 
Cell Biol, 20 (2008) 194-200. 
[14] M. Genander, M.M. Halford, N.J. Xu, M. Eriksson, Z. Yu, Z. Qiu, A. Martling, G. Greicius, 
S. Thakar, T. Catchpole, M.J. Chumley, S. Zdunek, C. Wang, T. Holm, S.P. Goff, S. 
Pettersson, R.G. Pestell, M. Henkemeyer, J. Frisen, Dissociation of EphB2 signaling 
pathways mediating progenitor cell proliferation and tumor suppression, Cell, 139 (2009) 
679-692. 
[15] E. Batlle, J. Bacani, H. Begthel, S. Jonkheer, A. Gregorieff, M. van de Born, N. Malats, 
E. Sancho, E. Boon, T. Pawson, S. Gallinger, S. Pals, H. Clevers, EphB receptor activity 
suppresses colorectal cancer progression, Nature, 435 (2005) 1126-1130. 
[16] C. Cortina, S. Palomo-Ponce, M. Iglesias, J.L. Fernandez-Masip, A. Vivancos, G. 
Whissell, M. Huma, N. Peiro, L. Gallego, S. Jonkheer, A. Davy, J. Lloreta, E. Sancho, E. 
Batlle, EphB-ephrin-B interactions suppress colorectal cancer progression by 
compartmentalizing tumor cells, Nat Genetics, 39 (2007) 1376-1383. 
[17] M. van de Wetering, E. Sancho, C. Verweij, W. de Lau, I. Oving, A. Hurlstone, K. van der 
Horn, E. Batlle, D. Coudreuse, A.P. Haramis, M. Tjon-Pon-Fong, P. Moerer, M. van den 
Born, G. Soete, S. Pals, M. Eilers, R. Medema, H. Clevers, The beta-catenin/TCF-4 
complex imposes a crypt progenitor phenotype on colorectal cancer cells, Cell, 111 
(2002) 241-250. 
[18] L.G. van der Flier, H. Clevers, Stem cells, self-renewal, and differentiation in the 
intestinal epithelium, Ann Rev Physiol, 71 (2009) 241-260. 
[19] L.E. Dow, K.P. O'Rourke, J. Simon, D.F. Tschaharganeh, J.H. van Es, H. Clevers, S.W. 
Lowe, Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt 
Homeostasis in Colorectal Cancer, Cell, 161 (2015) 1539-1552. 
[20] K.M. Cadigan, M.L. Waterman, TCF/LEFs and Wnt signaling in the nucleus, Cold Spring 
Harbor perspectives in biology, 4 (2012). 
[21] F.A. Atcha, A. Syed, B. Wu, N.P. Hoverter, N.N. Yokoyama, J.H. Ting, J.E. Munguia, 
H.J. Mangalam, J.L. Marsh, M.L. Waterman, A unique DNA binding domain converts T-
cell factors into strong Wnt effectors, Mol Cell Biol, 27 (2007) 8352-8363. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
30 
[22] N.P. Hoverter, M.D. Zeller, M.M. McQuade, A. Garibaldi, A. Busch, E.M. Selwan, K.J. 
Hertel, P. Baldi, M.L. Waterman, The TCF C-clamp DNA binding domain expands the 
Wnt transcriptome via alternative target recognition, Nucl Acids Res, 42 (2014) 13615-
13632. 
[23] B. Wallmen, M. Schrempp, A. Hecht, Intrinsic properties of Tcf1 and Tcf4 splice variants 
determine cell-type-specific Wnt/beta-catenin target gene expression, Nucl Acids Res, 
40 (2012) 9455-9469. 
[24] A. Weise, K. Bruser, S. Elfert, B. Wallmen, Y. Wittel, S. Wohrle, A. Hecht, Alternative 
splicing of Tcf7l2 transcripts generates protein variants with differential promoter-binding 
and transcriptional activation properties at Wnt/beta-catenin targets, Nucl Acids Res, 38 
(2010) 1964-1981. 
[25] K. Rönsch, M. Jäger, A. Schopflin, M. Danciu, S. Lassmann, A. Hecht, Class I and III 
HDACs and loss of active chromatin features contribute to epigenetic silencing of CDX1 
and EPHB tumor suppressor genes in colorectal cancer, Epigenetics, 6 (2011) 610-622. 
[26] D.L. Guo, J. Zhang, S.T. Yuen, W.Y. Tsui, A.S. Chan, C. Ho, J. Ji, S.Y. Leung, X. Chen, 
Reduced expression of EphB2 that parallels invasion and metastasis in colorectal 
tumours, Carcinogenesis, 27 (2006) 454-464. 
[27] A. Lugli, H. Spichtin, R. Maurer, M. Mirlacher, J. Kiefer, P. Huusko, D. Azorsa, L. 
Terracciano, G. Sauter, O.P. Kallioniemi, S. Mousses, L. Tornillo, EphB2 expression 
across 138 human tumor types in a tissue microarray: high levels of expression in 
gastrointestinal cancers, Clin Cancer Res, 11 (2005) 6450-6458. 
[28] K. Rönsch, S. Jägle, K. Rose, M. Seidl, F. Baumgartner, V. Freihen, A. Yousaf, E. 
Metzger, S. Lassmann, R. Schüle, R. Zeiser, T. Michoel, A. Hecht, SNAIL1 combines 
competitive displacement of ASCL2 and epigenetic mechanisms to rapidly silence the 
EPHB3 tumor suppressor in colorectal cancer, Molecular oncology, 9 (2015) 335-354. 
[29] I. Ovcharenko, M.A. Nobrega, G.G. Loots, L. Stubbs, ECR Browser: a tool for visualizing 
and accessing data from comparisons of multiple vertebrate genomes, Nucl Acids Res, 
32 (2004) W280-286. 
[30] X. Xie, P. Rigor, P. Baldi, MotifMap: a human genome-wide map of candidate regulatory 
motif sites, Bioinformatics, 25 (2009) 167-174. 
[31] A. Mathelier, X. Zhao, A.W. Zhang, F. Parcy, R. Worsley-Hunt, D.J. Arenillas, S. 
Buchman, C.Y. Chen, A. Chou, H. Ienasescu, J. Lim, C. Shyr, G. Tan, M. Zhou, B. 
Lenhard, A. Sandelin, W.W. Wasserman, JASPAR 2014: an extensively expanded and 
updated open-access database of transcription factor binding profiles, Nucl Acids Res, 
42 (2014) D142-147. 
[32] W.J. Kent, C.W. Sugnet, T.S. Furey, K.M. Roskin, T.H. Pringle, A.M. Zahler, D. 
Haussler, The human genome browser at UCSC, Genome Res, 12 (2002) 996-1006. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
31 
[33] D.L. Turner, H. Weintraub, Expression of achaete-scute homolog 3 in Xenopus embryos 
converts ectodermal cells to a neural fate, Genes Dev, 8 (1994) 1434-1447. 
[34] A. Hecht, M.P. Stemmler, Identification of a promoter-specific transcriptional activation 
domain at the C terminus of the Wnt effector protein T-cell factor 4, J Biol Chem, 278 
(2003) 3776-3785. 
[35] B.T. Preca, K. Bajdak, K. Mock, V. Sundararajan, J. Pfannstiel, J. Maurer, U. Wellner, 
U.T. Hopt, T. Brummer, S. Brabletz, T. Brabletz, M.P. Stemmler, A self-enforcing 
CD44s/ZEB1 feedback loop maintains EMT and stemness properties in cancer cells, Int 
J Cancer, 137 (2015) 2566-2577. 
[36] A. Welman, J. Barraclough, C. Dive, Generation of cells expressing improved 
doxycycline-regulated reverse transcriptional transactivator rtTA2S-M2, Nat Protocols, 1 
(2006) 803-811. 
[37] D. Cheasley, L. Pereira, S. Lightowler, E. Vincan, J. Malaterre, R.G. Ramsay, Myb 
controls intestinal stem cell genes and self-renewal, Stem cells, 29 (2011) 2042-2050. 
[38] V. Korinek, N. Barker, P. Moerer, E. van Donselaar, G. Huls, P.J. Peters, H. Clevers, 
Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-
4, Nat Genetics, 19 (1998) 379-383. 
[39] J. Malaterre, M. Carpinelli, M. Ernst, W. Alexander, M. Cooke, S. Sutton, S. Dworkin, 
J.K. Heath, J. Frampton, G. McArthur, H. Clevers, D. Hilton, T. Mantamadiotis, R.G. 
Ramsay, c-Myb is required for progenitor cell homeostasis in colonic crypts, Proc Natl 
Acad Sci USA, 104 (2007) 3829-3834. 
[40] A.K. San Roman, A. Tovaglieri, D.T. Breault, R.A. Shivdasani, Distinct Processes and 
Transcriptional Targets Underlie CDX2 Requirements in Intestinal Stem Cells and 
Differentiated Villus Cells, Stem Cell Rep, 5 (2015) 673-681. 
[41] D.Z. Ye, K.H. Kaestner, Foxa1 and Foxa2 control the differentiation of goblet and 
enteroendocrine L- and D-cells in mice, Gastroenterology, 137 (2009) 2052-2062. 
[42] M. Merika, D. Thanos, Enhanceosomes, Curr Opin Genet Dev, 11 (2001) 205-208. 
[43] Y. Nie, H. Liu, X. Sun, The patterns of histone modifications in the vicinity of transcription 
factor binding sites in human lymphoblastoid cell lines, PLOS ONE, 8 (2013) e60002. 
[44] P. Hatzis, L.G. van der Flier, M.A. van Driel, V. Guryev, F. Nielsen, S. Denissov, I.J. 
Nijman, J. Koster, E.E. Santo, W. Welboren, R. Versteeg, E. Cuppen, M. van de 
Wetering, H. Clevers, H.G. Stunnenberg, Genome-wide pattern of TCF7L2/TCF4 
chromatin occupancy in colorectal cancer cells, Mol Cell Biol, 28 (2008) 2732-2744. 
[45] M.P. Verzi, P. Hatzis, R. Sulahian, J. Philips, J. Schuijers, H. Shin, E. Freed, J.P. Lynch, 
D.T. Dang, M. Brown, H. Clevers, X.S. Liu, R.A. Shivdasani, TCF4 and CDX2, major 
transcription factors for intestinal function, converge on the same cis-regulatory regions, 
Proc Natl Acad Sci USA, 107 (2010) 15157-15162. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
32 
[46] E. Suh, L. Chen, J. Taylor, P.G. Traber, A homeodomain protein related to caudal 
regulates intestine-specific gene transcription, Mol Cell Biol, 14 (1994) 7340-7351. 
[47] B.A. Benayoun, S. Caburet, R.A. Veitia, Forkhead transcription factors: key players in 
health and disease, Trends Genet, 27 (2011) 224-232. 
[48] L.A. Cirillo, K.S. Zaret, Specific interactions of the wing domains of FOXA1 transcription 
factor with DNA, J Mol Biol, 366 (2007) 720-724. 
[49] K. Ogata, S. Morikawa, H. Nakamura, A. Sekikawa, T. Inoue, H. Kanai, A. Sarai, S. Ishii, 
Y. Nishimura, Solution structure of a specific DNA complex of the Myb DNA-binding 
domain with cooperative recognition helices, Cell, 79 (1994) 639-648. 
[50] C. Zhang, L. Wang, D. Wu, H. Chen, Z. Chen, J.M. Thomas-Ahner, D.L. Zynger, J. 
Eeckhoute, J. Yu, J. Luo, M. Brown, S.K. Clinton, K.P. Nephew, T.H. Huang, W. Li, Q. 
Wang, Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit 
in castration-resistant prostate cancer, Cancer Res, 71 (2011) 6738-6748. 
[51] A. Jolma, Y. Yin, K.R. Nitta, K. Dave, A. Popov, M. Taipale, M. Enge, T. Kivioja, E. 
Morgunova, J. Taipale, DNA-dependent formation of transcription factor pairs alters their 
binding specificity, Nature, 527 (2015) 384-388. 
[52] R.J. Guo, E.R. Suh, J.P. Lynch, The role of Cdx proteins in intestinal development and 
cancer, Cancer Biol Therapy, 3 (2004) 593-601. 
[53] A. Hryniuk, S. Grainger, J.G. Savory, D. Lohnes, Cdx function is required for 
maintenance of intestinal identity in the adult, Dev Biol, 363 (2012) 426-437. 
[54] M.P. Verzi, H. Shin, L.L. Ho, X.S. Liu, R.A. Shivdasani, Essential and redundant 
functions of caudal family proteins in activating adult intestinal genes, Mol Cell Biol, 31 
(2011) 2026-2039. 
[55] A.M. Zorn, J.M. Wells, Vertebrate endoderm development and organ formation, Ann Rev 
Dev Biol, 25 (2009) 221-251. 
[56] J. Munoz, D.E. Stange, A.G. Schepers, M. van de Wetering, B.K. Koo, S. Itzkovitz, R. 
Volckmann, K.S. Kung, J. Koster, S. Radulescu, K. Myant, R. Versteeg, O.J. Sansom, 
J.H. van Es, N. Barker, A. van Oudenaarden, S. Mohammed, A.J. Heck, H. Clevers, The 
Lgr5 intestinal stem cell signature: robust expression of proposed quiescent '+4' cell 
markers, EMBO J, 31 (2012) 3079-3091. 
[57] T. Pukrop, D. Gradl, K.A. Henningfeld, W. Knochel, D. Wedlich, M. Kuhl, Identification of 
two regulatory elements within the high mobility group box transcription factor XTCF-4, J 
Biol Chem, 276 (2001) 8968-8978. 
[58] N.P. Hoverter, J.H. Ting, S. Sundaresh, P. Baldi, M.L. Waterman, A WNT/p21 circuit 
directed by the C-clamp, a sequence-specific DNA binding domain in TCFs, Mol Cell 
Biol, 32 (2012) 3648-3662. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
33 
[59] S. Wöhrle, B. Wallmen, A. Hecht, Differential control of Wnt target genes involves 
epigenetic mechanisms and selective promoter occupancy by T-cell factors, Mol Cell 
Biol, 27 (2007) 8164-8177. 
[60] K. Rai, S. Sarkar, T.J. Broadbent, M. Voas, K.F. Grossmann, L.D. Nadauld, S. 
Dehghanizadeh, F.T. Hagos, Y. Li, R.K. Toth, S. Chidester, T.M. Bahr, W.E. Johnson, B. 
Sklow, R. Burt, B.R. Cairns, D.A. Jones, DNA demethylase activity maintains intestinal 
cells in an undifferentiated state following loss of APC, Cell, 142 (2010) 930-942. 
[61] C. Jamora, R. DasGupta, P. Kocieniewski, E. Fuchs, Links between signal transduction, 
transcription and adhesion in epithelial bud development, Nature, 422 (2003) 317-322. 
[62] T.A. Blauwkamp, M.V. Chang, K.M. Cadigan, Novel TCF-binding sites specify 
transcriptional repression by Wnt signalling, EMBO J, 27 (2008) 1436-1446. 
[63] T. Hinoi, M. Loda, E.R. Fearon, Silencing of CDX2 expression in colon cancer via a 
dominant repression pathway, J Biol Chem, 278 (2003) 44608-44616. 
[64] S. Guaita, I. Puig, C. Franci, M. Garrido, D. Dominguez, E. Batlle, E. Sancho, S. Dedhar, 
A.G. De Herreros, J. Baulida, Snail induction of epithelial to mesenchymal transition in 
tumor cells is accompanied by MUC1 repression and ZEB1 expression, J Biol Chem, 
277 (2002) 39209-39216. 
[65] D. Medici, E.D. Hay, B.R. Olsen, Snail and Slug promote epithelial-mesenchymal 
transition through beta-catenin-T-cell factor-4-dependent expression of transforming 
growth factor-beta3, Mol Biol Cell, 19 (2008) 4875-4887. 
[66] G. Solanas, M. Porta-de-la-Riva, C. Agusti, D. Casagolda, F. Sanchez-Aguilera, M.J. 
Larriba, F. Pons, S. Peiro, M. Escriva, A. Munoz, M. Dunach, A.G. de Herreros, J. 
Baulida, E-cadherin controls beta-catenin and NF-kappaB transcriptional activity in 
mesenchymal gene expression, J Cell Sci, 121 (2008) 2224-2234. 
[67] K. Kratochwil, M. Dull, I. Farinas, J. Galceran, R. Grosschedl, Lef1 expression is 
activated by BMP-4 and regulates inductive tissue interactions in tooth and hair 
development, Genes Dev, 10 (1996) 1382-1394. 
[68] A. Lorente-Trigos, F. Varnat, A. Melotti, A. Ruiz i Altaba, BMP signaling promotes the 
growth of primary human colon carcinomas in vivo, J Mol Cell Biol, 2 (2010) 318-332. 
[69] Y. Song, M.K. Washington, H.C. Crawford, Loss of FOXA1/2 is essential for the 
epithelial-to-mesenchymal transition in pancreatic cancer, Cancer Res, 70 (2010) 2115-
2125. 
[70] B. Tanno, F. Sesti, V. Cesi, G. Bossi, G. Ferrari-Amorotti, R. Bussolari, D. Tirindelli, B. 
Calabretta, G. Raschella, Expression of Slug is regulated by c-Myb and is required for 
invasion and bone marrow homing of cancer cells of different origin, J Biol Chem, 285 
(2010) 29434-29445. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
34 
[71] H.J. Hugo, L. Pereira, R. Suryadinata, Y. Drabsch, T.J. Gonda, N.P. Gunasinghe, C. 
Pinto, E.T. Soo, B.J. van Denderen, P. Hill, R.G. Ramsay, B. Sarcevic, D.F. Newgreen, 
E.W. Thompson, Direct repression of MYB by ZEB1 suppresses proliferation and 
epithelial gene expression during epithelial-to-mesenchymal transition of breast cancer 
cells, Breast Cancer Res, 15 (2013) R113. 
[72] S. Javaid, J. Zhang, E. Anderssen, J.C. Black, B.S. Wittner, K. Tajima, D.T. Ting, G.A. 
Smolen, M. Zubrowski, R. Desai, S. Maheswaran, S. Ramaswamy, J.R. Whetstine, D.A. 
Haber, Dynamic chromatin modification sustains epithelial-mesenchymal transition 
following inducible expression of Snail-1, Cell Rep, 5 (2013) 1679-1689. 
[73] M. Nicolau, A.J. Levine, G. Carlsson, Topology based data analysis identifies a 
subgroup of breast cancers with a unique mutational profile and excellent survival, Proc 
Natl Acad Sci USA, 108 (2011) 7265-7270. 
[74] M.M. Kulkarni, D.N. Arnosti, Information display by transcriptional enhancers, 
Development, 130 (2003) 6569-6575. 
[75] H. Alotaibi, M.F. Basilicata, H. Shehwana, T. Kosowan, I. Schreck, C. Braeutigam, O. 
Konu, T. Brabletz, M.P. Stemmler, Enhancer cooperativity as a novel mechanism 
underlying the transcriptional regulation of E-cadherin during mesenchymal to epithelial 
transition, Biochim Biophys Acta, 1849 (2015) 731-742. 
[76] B. Akhtar-Zaidi, R. Cowper-Sal-lari, O. Corradin, A. Saiakhova, C.F. Bartels, D. 
Balasubramanian, L. Myeroff, J. Lutterbaugh, A. Jarrar, M.F. Kalady, J. Willis, J.H. 
Moore, P.J. Tesar, T. Laframboise, S. Markowitz, M. Lupien, P.C. Scacheri, Epigenomic 
enhancer profiling defines a signature of colon cancer, Science, 336 (2012) 736-739. 
[77] G.R. Diaferia, C. Balestrieri, E. Prosperini, P. Nicoli, P. Spaggiari, A. Zerbi, G. Natoli, 
Dissection of transcriptional and cis-regulatory control of differentiation in human 
pancreatic cancer, EMBO J, (2016). 
[78] P.C. Taberlay, A.L. Statham, T.K. Kelly, S.J. Clark, P.A. Jones, Reconfiguration of 
nucleosome-depleted regions at distal regulatory elements accompanies DNA 
methylation of enhancers and insulators in cancer, Genome Res, 24 (2014) 1421-1432. 
[79] R.P. Koche, Z.D. Smith, M. Adli, H. Gu, M. Ku, A. Gnirke, B.E. Bernstein, A. Meissner, 
Reprogramming factor expression initiates widespread targeted chromatin remodeling, 
Cell Stem Cell, 8 (2011) 96-105. 
 
 
 
 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
35 
Figure legends 
 
Fig. 1. Features of active chromatin at the EPHB2 -8.4 kb enhancer are diminished upon 
expression of Snail1-HA. (A) Schematic representation of the human EPHB2 upstream 
region from -12 kb to the transcriptional start site (TSS) and Exon 1 (Ex1). ECR: 
Evolutionarily conserved regions with sequence identities of more than 70% are shown by 
grey boxes. DHS: Clusters of DNaseI hypersensitivity in HUVEC cells. H3K4me1, H3K27ac: 
Levels of enrichment of the H3K4me1 and H3K27ac histone marks across the genome as 
determined by ChIP-seq assays in HUVEC cells. (B) FAIRE analyses of the EPHB2 
upstream region in LS174T cells stably transduced with Dox-inducible control and Snail1-HA 
retroviral expression vectors. Cells were treated with 0.1 μg ml-1 Dox for 144 h or were left 
untreated. A region 11 kb upstream of the AXIN2 transcriptional start site served as negative 
control (- ctrl.). Data was calculated as relative enrichment of sequences of interest in 
formaldehyde-crosslinked versus non-crosslinked material. Shown are the mean and SEM; n 
= 3. n.s.: not significant. (C) ChIP analyses of H3, H3K4me1 and H3K27ac at positions -12.3 
kb and -8.4 kb relative to the EPHB2 transcriptional start site in LS174T cells stably 
transduced with Dox-inducible control and Snail1-HA retroviral expression vectors. Cells 
were treated with 0.1 μg ml-1 Dox for 0 h, 24 h and 96 h as indicated. Data was calculated as 
percent of input. In case of H3K4me1 and H3K27ac, enrichment was further normalized to 
H3 to account for regional differences in nucleosome density. Shown are the mean and 
SEM; n = 3. 
 
Fig. 2. Mapping of an EPHB2 minimal enhancer fragment with cell-type-specific activity. 
Luciferase reporter assays in four different CRC cell lines to narrow down the minimal cell-
type-specific enhancer region within the EPHB2 upstream region. The coordinates of the 
EPHB2 enhancer subfragments are shown relative to the transcriptional start site. LUC: 
Luciferase coding sequence. SV40: SV40 promoter sequence. Shown are the mean and 
SEM; n = 3. n.s.: not significant. 
 
Fig. 3. EPHB2 enhancer activity depends on CDX2, TCF/LEF, MYB, and FOX proteins. (A) 
Nucleotide sequence of the EPHB2 minimal enhancer region from -8398 bp to -8272 bp with 
binding sites for CDX2, TCF7L2, MYB and FOXA1 as predicted in silico. (B) Sequences of 
the predicted binding motifs for CDX2, TCF/LEF, MYB, and FOX proteins and the nucleotide 
exchanges introduced to abolish their binding. Mutated bases are shown in red. (C) EMSAs 
to analyze binding of recombinant CDX2, TCF7L2-E, MYB, and FOXA1 to the EPHB2 
minimal enhancer region in vitro. Note, that an E-type splice variant of TCF7L2 (TCF7L2-E) 
was used for the experiments [24]. Control samples received mock-programmed 
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transcription/translation mixes. Sequence changes in mutated probes are shown in (B). Non-
specific signals are labeled with asterisks. For each transcription factor one representative 
EMSA experiment is shown; n = 3. WT: wild-type; MUT: mutated. (D) Luciferase reporter 
assays in LS174T cells to identify functionally important transcription factor binding sites 
within the EPHB2 minimal enhancer region. Sequence changes in mutated (mut) probes are 
depicted in (B). Results shown are the mean and SEM; n = 3. 
 
Fig. 4. Snail1 inactivates the EPHB2 -8.4 kb enhancer by downregulation of FOXA1 and 
MYB. (A) qRT-PCR analyses of Snail1-HA, CDX2, FOXA1, and MYB expression relative to 
GAPDH (rel. expr.) in LS174T cells stably transduced with Dox-inducible control and Snail1-
HA retroviral expression vectors. Cells were treated with 0.1 μg ml-1 Dox for the indicated 
time periods. Shown are the mean and SEM; n = 3. (B) Western blot analyses of CDX2, 
FOXA1, and MYB in LS174T cells stably transduced with Dox-inducible control and Snail1-
HA retroviral expression vectors. RNA Polymerase II (POL2) immunodetection served as 
loading control. One representative example is shown; n = 3. (C) Pairwise correlation 
analyses of EPHB2, CDX2, MYB, FOXA1, TCF7L2, SNAI1, SNAI2, and ZEB1 expression in 
290 colorectal tumor samples (left) and 155 CRC cell lines (right). The red/blue color shading 
indicates the Pearson correlation coefficient as shown by the color bar. (D) ChIP analyses of 
MYB, FOXA1, and CDX2 at positions -12.3 kb and -8.4 kb relative to the EPHB2 
transcriptional start site in LS174T cells stably transduced with Dox-inducible control and 
Snail1-HA retroviral expression vectors. Cells were treated with 0.1 μg ml-1 Dox for the 
indicated time periods. Data was calculated as percent of input. Shown are the mean and 
SEM; n = 3. n.s.: not significant. 
 
Fig. 5. Snail1 overexpression induces a TCF7L2/LEF1 switch at the EPHB2 -8.4 kb 
enhancer. (A) qRT-PCR analyses of LEF1 and TCF7L2 expression relative to GAPDH (rel. 
expr.) in LS174T cells stably transduced with Dox-inducible control and Snail1-HA retroviral 
expression vectors. Cells were treated with 0.1 μg ml-1 Dox for the indicated time periods. 
Shown are the mean and SEM; n = 3. (B) Western blot analyses of LEF1 and TCF7L2 
expression in LS174T cells stably transduced with Dox-inducible control and Snail1-HA 
retroviral expression vectors. The positions of TCF7L2-E and TCF7L2-M/S splice variants 
are shown. Cells were treated with 0.1 μg ml-1 Dox for the indicated time periods. 
Immunodetection of α-TUBULIN (TUB) served as loading control. One representative 
example is shown; n = 3. (C) Competitive EMSA to compare affinity of LEF1 and TCF7L2-E 
for the TCF/LEF motif within the EPHB2 minimal enhancer region in vitro. Nucleotide 
sequences of wild-type and mutated probes are shown. The TCF/LEF binding motif is 
highlighted by bold letters and nucleotide exchanges are indicated in red. Western blot 
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analysis of in vitro translated (IVT) TCF7L2-E and LEF1 proteins (left) and one 
representative example for the EMSA results (right) are shown; n = 3. Non-specific signals in 
the EMSA are labeled with asterisks. (D) ChIP analyses of TCF7L2 and LEF1 at positions 
12.3 kb and -8.4 kb relative to the EPHB2 TSS in LS174T cells stably transduced with Dox-
inducible control and Snail1-HA retroviral expression vectors. Cells were treated with 0.1 μg 
ml-1 Dox for the indicated time periods. Data was calculated as percent of input. Shown are 
the mean and SEM; n = 3. 
 
Fig. 6. Overexpression of Lef1-HA is not sufficient to permanently downregulate EPHB2. (A) 
qRT-PCR analyses of Lef1-HA, EPHB2, SNAI1, FOXA1, MYB and CDX2 expression relative 
to GAPDH (rel. expr.) in LS174T cells stably transduced with Dox-inducible control and Lef1-
HA retroviral expression vectors. Cells were treated with 0.1 μg ml-1 Dox for the indicated 
time periods. Shown are the mean and SEM. n = 3. n.s.: not significant. (B) Western blot 
analyses of EPHB2, Lef1-HA, CDX2, FOXA1 and MYB expression in LS174T cells stably 
transduced with Dox-inducible control and Lef1-HA retroviral expression vectors. Cells were 
treated with 0.1 μg ml-1 Dox for the indicated time periods. TUB and POL2 immunodetection 
served as loading controls. Whole cell lysates and nuclear extracts were used for the 
experiments shown in the left and right parts of the panel, respectively. One representative 
example is shown; n = 3. (C) ChIP analyses of Lef1-HA and TCF7L2 at EPHB2 -12.3 kb and 
-8.4 kb in LS174T cells, stably transduced with Dox-inducible control and Lef1-HA retroviral 
expression vectors, treated with 1.0 μg ml-1 Dox for the indicated time periods. Data was 
calculated as percent of input. Shown are the mean and SEM; n = 3. (D) ChIP analyses of 
FOXA1, MYB and CDX2 at EPHB2 -12.3 kb and -8.4 kb in LS174T cells, stably transduced 
with Dox-inducible control and Lef1-HA retroviral expression vectors, treated with 0.1 μg ml-1 
Dox for the indicated time periods. Data was calculated as percent of input. Shown are the 
mean and SEM; n = 3. n.s.: not significant. (E) Model for Snail1-mediated silencing of 
EPHB2 expression through inactivation of the EPHB2 enhancer by competitive displacement 
and deprivation of its constituent transcriptional activators. 
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Table 1: Sequences of oligonucleotides used for PCR, mutagenesis, quantitative RT-
PCR, EMSA, FAIRE and ChIP 
Oligonucleotides for PCR: 
Primer: Forward (5‘-3‘) Reverse (5‘-3‘) 
EPHB2 
-8841/-7618  
TCACGCGTAGAAGCCTGCCTGCTTATCA CTGCTAGCCCTGACACATGGGCACTGAC  
EPHB2 
-8841/-8041  
TCACGCGTAGAAGCCTGCCTGCTTATCA CTGCTAGCGTCTCCCAATTCCCCAGATT  
EPHB2 
-8462/-7618  
TCACGCGTGCACCTCTGTTACCAGGAACC  CTGCTAGCCCTGACACATGGGCACTGAC  
EPHB2 
-8462/-8041  
TCACGCGTGCACCTCTGTTACCAGGAACC CTGCTAGCGTCTCCCAATTCCCCAGATT  
EPHB2 
-8398/-8272  
TCACGCGTGGTCGGCCAGGGGAATAGCC  
CTGCTAGCGGAGTGCCGATCCAGGTAAAA
G 
EPHB2 
-8398/-8330  
GGTCGGCCAGGGGAATAGCCATAAAATTC
TGTGTGCTCCTGTGGGGCGCAAAGATCAA
AGTATCCCATG 
CTAGCATGGGATACTTTGATCTTTGCGCCC
CACAGGAGCACACAGAATTTTATGGCTATT
CCCCTGGCCGACCGAGCT 
EPHB2 
-8350/-8272  
CCAAAGATCAAAGTATCCCATATCAGTCTC
AGTATACAACCGTAACAACATAACAACCTT
TTACCTGGATACGGCACTCCG  
CTAGCGGAGTGCCGTATCCAGGTAAAAGG
TTGTTATGTTGTTACGGTTGTATACTGAGA
CTGATATGGGATACTTTGATCTTTGGAGCT  
EPHB2 
-8350/-8330  
CCAAAGATCAAAGTATCCCATG   CTAGCATGGGATACTTTGATCTTTGGAGCT 
EPHB2 
-11073/-
10237 
TCACGCGTAAAATGGCGAGAACAACCAG   CTGCTAGCGACATGAGCCACCATACACG 
EPHB2 
-6453/-5951  
GAACGCGTAAGAGGTGGTGCTGGATTTG  CTGCTAGCGTGATGGGCCGTGAAACCAG  
Oligonucleotides for mutagenesis (mutated bases underlined): 
Primer: Forward (5‘-3‘) Reverse (5‘-3‘) 
CDX2 
CGGCCAGGGGAATAGCCAGCCGATTCTGT
GTGCTCCTGTGGGG 
CCCCACAGGAGCACACAGAATCGGCTGGC
TATTCCCCTGGCCG 
TCF/LEF 
GCTCCTGTGGGGCGCAATGGCCAAAGTAT
CCCATATC 
GATATGGGATACTTTGGCCATTGCGCCCC
ACAGGAG  
FOX/MYB 
TCCCATATCAGTCTCAGTATACCCCCGTAA
CAACATAACAAC 
GTTGTTATGTTGTTACGGGGGTATACTGAG
ACTGATATGGGA 
Oligonucleotides for quantitative RT-PCR: 
Primer: Forward (5‘-3‘) Reverse (5‘-3‘) 
EPHB2 AGTTCGGCCAAATTGTCAAC  TCTCCTTGTACTGCCCCATC  
Lef1-HA  TATGAACAGCGACCCGTACA  TCGTCGCTGTAGGTGATGAG  
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LEF1  CGAATGTCGTTGCTGAGTGT  GCAGACCAGCCTGGATAAAG  
Snail1-HA  CTTGTGTCTGCACGACCTGT CTTCACATCCGAGTGGGTTT  
SNAI1  TTTACCTTCCAGCAGCCCTA  CCTCATCTGACAGGGAGGTC  
TCF7L2  TGCGTTCGCTACATACAAGG  TGGGTCTGCTCAGTCTGTGA  
CDX2 CCCGAACAGGGACTTGTTTA AGACCAACAACCCAAACAGC 
MYB ACAGATGGGCAGAAATCGCA GCTGGCTGGCTTTTGAAGAC 
FOXA1 AGCAGCAGCATAAGCTGGAC GTGTTTAGGACGGGTCTGGA 
SNAI2 GAGCATTTGCAGACAGGTCA GCTTCGGAGTGAAGAAATGC 
SNAIL2-HA GAGCATTTGCAGACAGGTCA GGACGTCATAAGGATATCCAGCA 
ZEB1 CCTTAAGCAAGACCTGTGTGC CCGAGGAATTGAAGGATGAA 
ZEB1-HA CACCAAGTGCCAACCCCATA CAGGGCTGACCGTAGTTGAG 
BMP2 GTCCCGACAGAACTCAGTGC TCAACTGGGGTGGGGTTTTT 
BMP4 TGTTGTGTGCCCACTGAACT TGAGTGGATGGGAACGTGTG 
Oligonucleotides for EMSA (biotinylated):  
Primer: Forward (5‘-3‘) Reverse (5‘-3‘) 
EPHB2 
-8398/-8272  
TCACGCGTGGTCGGCCAGGGGAATAGCC  CTGCTAGCGGAGTGCCGTATCCAGGTAAA
AG 
Oligonucleotides for FAIRE and ChIP: 
Primer: Forward (5‘-3‘) Reverse (5‘-3‘) 
AXIN2  TTGACCTCGGGAATCTGTTC CCATCCCCACCTTCTCTTCT 
EPHB2 -12.3 GGTGGGAGGACAACAGACAC  CTACAGCAGGAGCTGGGAAC  
EPHB2 -11.2 ATGCATGCGGAGCTTAAAAC  TGGCAGTTGGAAGAATCCTG 
EPHB2 -10.6 TCCACCTCAGACAGTTGCAG GACATGAGCCACCATACACG 
EPHB2 -9.3 AGAGAATTTGGGGCAGTGAA  AGGTTGAGGCTGCAGTGAGT  
EPHB2 -8.4 CAGGAGAGACGCAGATTG AAGGTTGTTATGTTGTTACGG 
EPHB2 -7.2 TGAAGTTTGAGGCTGCAATG GCCTTTGGAGTTAGGGAAGG 
EPHB2 -6.2 AGGGGTCAAAAGTGGAAACC TGTGACTCAGAGCTGGAGGA 
EPHB2 -5.8 AACCCAAGGGAATGCTCACT AATCTCCACAGCCTGAGAGC 
EPHB2 -4.0 CTGGCTGTAGGGATGGTTTG GGGGGAAACATGTTACACTGA 
EPHB2 -3.3 CCCTGATGTAACCTCCTCCA ATCAGGGAAGGCCTCTTAGG 
EPHB2 -2.6 CTTAAACCGCCTCCTCCTCT ACATGGTCCATTGCTGGTTT 
EPHB2 -1.3 CTCCCTGCTCACTCCTGTTC TACCACAGGCTTTGGGAATC 
EPHB2 -0.3 GGCTTTGCAGCATTCAATAA CGCAGCAGTGGTCTCTCC 
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Highlights 
- Epithelial-mesenchymal transition leads to repression of EPHB2 in colorectal cancer 
- EPHB2 expression depends on a transcriptional enhancer 
- FOXA1, MYB, CDX2 and the Wnt pathway effector TCF7L2 are EPHB2 enhancer factors 
- SNAIL1-induced expulsion of TCF7L2 by repressive LEF1 impairs EPHB2 enhancer 
activity 
- SNAIL1 represses FOXA1 and MYB for further activator deprivation of the enhancer 
